

**INFORMAZIONI
PERSONALI****MASSIMO COLLINO**

📍 Dipartimento di Neuroscienze “Rita Levi Montalcini” –
Università di Torino,
Via P. Giuria 9. 10125 Torino (Italy)

✉ massimo.collino@unito.it

🔗 https://www.neuroscienze.unito.it/do/docenti.pl/Show?_id=mcollino#tab-profilo

ORCID ID: <https://orcid.org/0000-0001-8782-3496>

SCOPUS ID: 6506832448

Web of Science ResearcherID: AAK-8532-2020

Sesso M | Data di nascita 19/01/1973 | Nazionalità ITALIANA

Codice Fiscale CLLMSM73A19G674G

**QUALIFICA
PROFESSIONALE****Professore Ordinario (SSD BIO/14 – Farmacologia)****SEDE DI SERVIZIO**

Dipartimento di Neuroscienze “Rita Levi Montalcini”,
Università degli Studi di Torino
Via P. Giuria 9, 10125 Torino

**INFORMAZIONI
RELATIVE AL
PERCORSO
SCIENTIFICO
E PROFESSIONALE:**

- ❖ Laurea in Chimica e Tecnologia Farmaceutiche (17 marzo 1998, massimo dei voti e lode)
- ❖ Abilitazione all’esercizio della professione di Farmacista (1998, II sessione)
- ❖ Dottorato in Farmacologia e Tossicologia (31-1-2003) , Università degli Studi di Torino.
- ❖ Ricercatore presso la Facoltà di Farmacia, Università di Torino negli anni 2002-2014
- ❖ Professore Associato presso l’Università di Torino negli anni 2014-2021

Visiting Scientist

2003-2004: presso il William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, University of London, London (UK)

Visiting Professor:

2020-2022: Visiting Professor in Pharmacology at the Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel (Dozor Visiting Scholar)

**ESPERIENZE
PROFESSIONALI**

- 2019 ad oggi **Membro del Gruppo di Lavoro sui Botanicals presso l'Autorità Europea per la Sicurezza Alimentare (EFSA)**
- 2020-2023 **Componente del Comitato Etico** Interaziendale A.O.U. San Luigi Gonzaga di Orbassano e AA.SS.LL. TO3-TO4-TO5
- 2015-2019 **Componente del Comitato Etico** Interaziendale ASO S. Croce e Carle, AA.SS.LL CN1, CN2 e AT (due mandati)
- 2020 ad oggi **Direttore del Master** di II Livello in Farmacia Territoriale “Chiara Colombo”, Università di Torino
- 2018-2020 **Membro del Comitato Scientifico** del Master di II Livello in Farmacia Territoriale “Chiara Colombo”, Università di Torino
- 2020-2021 **Visiting Professor** in Pharmacology at the Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel (Dozor Visiting Scholar)
- 2014 ad oggi **Valutatore esperto per il MIUR** (Adesione Albo dei Revisori dal 2012) nei settori ERC: LS7_3 (Pharmacology, pharmacogenomics, drug discovery and design, drug therapy); LS4_7 (Cardiovascular diseases); LS4_5 (Metabolism, biological basis of metabolism related disorders). Esperto Valutatore per prodotti VQR 2011-2014
- 2014 ad oggi **Valutatore di progetti per l'attribuzione di fondi di ricerca da parte delle seguenti istituzioni internazionali:**
- Medical Research Council (United Kingdom)
 - Diabetes UK Research Network (United Kingdom)
 - Estonian Research Council (Estonia)
 - Israel Science Foundation (Israel)
 - National Science Center of Poland (Poland)
 - Netherlands Organisation for Scientific Research (NWO/ZonMw),
- Reclutamento di personale universitario:**
- 2020 Membro della Commissione Esaminatrice del concorso pubblico per titoli ed esami per tecnico addetto alla ricerca dipartimentale presso l'Università di Firenze
- 2020 Membro della Commissione Esaminatrice del concorso per posti di Ricercatore a Tempo Determinato ai sensi dell'art. 24, comma 3, lett. a) Legge 240/2010 - settore concorsuale 05/G1 (Farmacologia, farmacologia clinica e farmacognosia) – S.S.D. BIO/14 (Farmacologia) presso l'Università di Torino

- 2014-2019 **Membro Scientifico dell'Organismo preposto al benessere animale (OPBA)**, istituito ai sensi dell'art. 25, a cui il D. Lgs. n. 26/2014 con il compito di esprimere parere motivato sui progetti di ricerca afferenti allo stabulario del Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino
- 2020 ad oggi **Responsabile dell'Organismo preposto al benessere animale (OPBA)**, Stabulario del Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino
- 2015 ad oggi **Attività di consulenza** per le società MA Provider (Roma); Nadirex International Srl (Pavia), Gradenigo Srl (Torino), Farmaservizi Piemonte (Torino) per l'organizzazione di eventi formativi con accreditamento ECM per medici e farmacisti.
- 2016 ad oggi **Attività di consulenza** per le aziende Pierre Fabre Italia S.p.A., Mylan Italia S.r.l. e Grünenthal Italia S.r.l..per le attività di accesso al mercato di prodotti farmaceutici.
- 2018 ad oggi **Membro del Comitato Scientifico** del Settore Formazione ECM del Centro Pediatrico Torino (C.P.G s.r.l.)
- 2003-2004 **Visiting Scientist** presso il William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, University of London, London (UK)

ATTIVITA' DIDATTICA

Affidamento di corsi di insegnamento in corsi di Laurea

- 2021 ad oggi Docente del corso di insegnamento “**Farmacologia I**” nel Corso di Laurea Magistrale in **Medicina e Chirurgia** - sede di Torino - Università di Torino
- 2021 ad oggi Docente del corso di insegnamento “**Farmacologia II**” nel Corso di Laurea Magistrale in **Medicina e Chirurgia** - sede di Torino - Università di Torino
- 2021 ad oggi Docente del corso di insegnamento “**Pharmacology**” nel Corso di Laurea Magistrale in **Medicina e Chirurgia** - sede di Orbassano, San Luigi Gonzaga - Università di Torino
- 2021 ad oggi Docente del corso di insegnamento “**Neuropharmacology**” nel Corso di Laurea Magistrale in “**Biotechnology for Neuroscience**”- Università di Torino
- 2017 ad oggi Docente del corso di insegnamento “**Farmacoterapia**” nel Corso di Laurea Magistrale in **Farmacia** - Università di Torino
- 2005 ad oggi Docente del corso di insegnamento “**Tossicologia**” nel Corso di Laurea Magistrale in **Chimica e Tecnologia Farmaceutiche** - Università di Torino
- 2015 ad oggi Docente del corso di insegnamento “**Bioteecnologie Farmacologiche e Tossicologiche**” nel Corso di Laurea Magistrale in **Chimica e Tecnologia Farmaceutiche** - Università di Torino
- 2015-2018 Docente del corso di insegnamento “**Tossicologia**” nel Corso di Laurea Magistrale in **Farmacia** - Università di Torino
- 2005-2015 Docente del corso di insegnamento “**Tossicologia**” nel Corso di Laurea in Tecniche Erboristiche - Università di Torino
- 2005-2017 Docente del corso di insegnamento “**Interazioni tra farmaci e prodotti di origine vegetale** ” nel Corso di Laurea in Tecniche Erboristiche - Università di Torino
- 2012-2015 Docente del corso di insegnamento “**Le piante, la società, la terapia: piante usate nelle medicine tradizionali, meccanismi farmacologici**”

e sicurezza d'uso" nel Corso di Laurea Magistrale in **Farmacia** -
Università di Torino

2015-2018 Docente del corso di insegnamento "**Criteri di valutazione farmacologica di medicinali equivalenti e biosimilari, SOP e OTC: il consiglio a banco del Farmacista**" nel Corso di Laurea Magistrale in Farmacia - Università di Torino

*I corsi di insegnamento sopra indicati hanno sempre ottenuto valutazioni di "**completa soddisfazione**" da parte degli studenti (questionari on line EduMeter, Università di Torino, a.a. 2013-2014 ad oggi)*

Affidamento di corsi di insegnamento in
Scuole di Specializzazione

- 2017 ad oggi Docente del corso di insegnamento “**Farmacologia**” presso le seguenti **Scuole di Specializzazione** dell’Università di Torino:
- Chirurgia Maxillo Facciale
 - Medicina dello Sport
 - Farmacia Ospedaliera
 - Audiologia e Foniatria
 - Scienza dell’Alimentazione

Affidamento di corsi di insegnamento in
Master Universitari e Dottorati di Ricerca

- 2016 ad oggi Docente del corso di insegnamento “Interazioni tra farmaci ed integratori alimentari: il consiglio a banco” nel **Master Universitario di II Livello in Farmacia Territoriale** "Chiara Colombo" – Università di Torino
- 2013-2014 Docente del corso di insegnamento “Meccanismi farmacologici della terapia del dolore e nuove prospettive farmacoterapeutiche” nel **Master Universitario** in Psico-oncologia – Università di Torino
- 2016-2017
2019-2020 Docente del corso di insegnamento “Advances in Pharmacology” nel **Dottorato di Ricerca** in Scienze Farmaceutiche e Biomolecolari della Scuola di Dottorato in Scienza dalla Natura e Tecnologie Innovative dell’Università degli Studi di Torino

Dottorato di Ricerca

- 2012 ad oggi **Membro del Collegio dei Docenti del Dottorato di Ricerca** in Scienze Farmaceutiche e Biomolecolari della Scuola di Dottorato in Scienza dalla Natura e Tecnologie Innovative dell’Università degli Studi di Torino
- 2012-2015
- 2017-2020
- 2019-2022
- 2020-2023
- **Supervisore** di un candidato iscritto al XXIX Ciclo
 - **Supervisore** di un candidato iscritto al XXXIII Ciclo
 - **Supervisore** di un candidato iscritto al XXXV Ciclo
 - **Mentore** di un candidato iscritto presso l’Institute of Nutritional Sciences, University of Hohenheim, Germany

Membro delle seguenti **Commissione Esaminatrice per il conferimento del titolo di Dottore di Ricerca:**

- 2018 Dottorato di Ricerca in “Scienze Farmaceutiche e Biomolecolari” dell’Università degli Studi di Torino, febbraio 2018
- 2018 Dottorato di Ricerca in “Chemistry and Biology” dell’Università degli studi del Piemonte Orientale, 13 marzo 2018
- 2020 Programa de Doctorado “Biomedicina y Oncología Molecular”, University of Oviedo, SPAIN, 15 ottobre 2020
- 2020 Dottorato di Ricerca in “Medicin e Terapia Sperimentale” dell’Università degli Studi di Torino, dicembre 2020

Valutatore Esterno per le seguenti Tesi di Dottorato di Ricerca:

- 2013 PhD in Pharmaceutical Science – Andhra University, Visakhapatnam–Andhra Pradesh, India, July 2013 (titolo tesi “Studies on cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats”)
- 2016 Dottorato di Ricerca in Scienze Biomediche Cliniche e Sperimentali, XXIX ciclo, dell’Università di Messina, dicembre 2016 (titolo tesi “Therapeutic angiogenesis in diabetes-related impaired wound healing”)
- 2020 Dottorato di Ricerca in Scienza del Farmaco, Università degli Studi di Napoli “Federico II” XXXII ciclo, gennaio 2020 (titolo tesi “Pharmacological effects of palmitoyethanolamide, an endogenous N-acylethanolamines in modulation of mitochondrial and metabolic function”)

Mobilità Internazionale

2009 ad oggi

Docente del Teaching staff per l'**accordo ERASMUS** tra l’Università di Torino e il Queen Mary and Westfield College University of London (London, UK).

- **Lezioni e seminari** svolti presso la School of Medicine and Dentistry, **Queen Mary University of London** negli anni 2009-2011-2012-2013-2015-2016, 2017, 2018, 2019

2017 ad oggi

Responsabile Scientifico del progetto di mobilità internazionale extra-europeo Erasmus+ tra l’Università di Torino e l’Università Ben Gurion del Negev (Beer Sheva, Israele) (bando Erasmus+ call 2017 Grant Agreement Number 2017-1-IT02-KA107-036256).

- **Lezioni e seminari** tenuti presso la School of Pharmacy dell’**Università Ben Gurion del Negev** nei mesi di febbraio-marzo 2018, marzo 2019 e maggio 2022

- 2020 Partecipazione al Corso “English as a Medium of Instruction”, British Council, Settembre 2020

**Commissioni
Esaminatrici**

2012 e 2015

Membro della Commissione Esaminatrice per l'**Esame di Stato di abilitazione all'esercizio della professione di FARMACISTA**
Università di Torino

2020

Presidente della Commissione Esaminatrice per l'Esame di Stato di abilitazione all'esercizio della professione di FARMACISTA
Università di Torino

**Relatore di Tesi di
Laurea
FARMACIA****TESI COMPILATIVE:**

- Marinelli Alfredo (a.a. 2005-2006)
- D'Amelio Marco (a.a. 2011-2012)
- Osella Paola (a.a. 2012-2013)
- Sacco Elena (a.a. 2012-2013)
- Picollo Alessandra (a.a. 2012-2013)
- Soro Valeria (a.a. 2013-2014)
- Gemelli Lorenzo (a.a. 2015-2016)
- Sorrenti Chiara (a.a. 2017-2018)
- Del Popolo Carlo (a.a. 2017-2018)
- Saleh Jamal (a.a. 2017-2018)
- Maniero Beatrice (a.a. 2018-2019)
- Giaccone Luisa (a.a. 2019-2020)
- Poncet Carlotta (a.a. 2020-2021)
- Zavatteri Martina (a.a. 2020-2021)

TESI SPERIMENTALI:

- Ravetto Valentina (a.a. 2015-2016)
- De Rosa Simona (a.a. 2016-2017)
- Cornaglia Andrea (a.a. 2016-2017)
- Rubicondo Ombretta (a.a. 2017-2018)
- Addamo Federica (a.a. 2017-2018)
- Piccardo Giulia (a.a. 2017-2018)
- Ricca Giulia (a.a. 2017-2018)
- Stafa Flogerta (a.a. 2017-2018)
- Gatti Elisabetta (a.a. 2017-2018)
- Castelli Serena (a.a. 2017-2018)
- Bastonero Elena (a.a. 2017-2018)
- Rizzo Raffaella (a.a. 2017-2018)
- Giorgia Salera (a.a. 2017-2018)
- Oggero Elisa (a.a. 2018-2019)

- Mirabello Claudia (a.a. 2018-2019)
- Cavallero Marta (a.a. 2018-2019)
- Aimaretti Eleonora (a.a. 2019-2020)
- Mulè Barbara (a.a. 2019-2020)
- Esposito Giulia (a.a. 2019-2020)
- Berbotto Clara (a.a. 2019-2020)

**CHIMICA E
TECNOLOGIA
FARMACEUTICHE**

TESI SPERIMENTALI:

- Romagnolo Andrea (a.a. 2007-2008)
- Rogazzo Mara (a.a. 2009-2010)
- Chiazza Fausto (a.a. 2011-2012)
- Tripoli Ezio (a.a. 2011-2012)
- Filetti Maria Catena (a.a. 2012-2013)
- Bressanello Davide (a.a. 2012-2013)
- Vanzetti Paola (a.a. 2012-2013)
- Esma Fabrizio (a.a. 2012-2013)
- Vitarelli Giovanna (a.a. 2013-2014)
- Rubietti Stefano (a.a. 2013-2014)
- Ferraro Rita (a.a. 2013-2014)
- Alu' Marco (a.a. 2013-2014)
- Pasquale Cinzia (a.a. 2013-2014)
- Varrone Barbara (a.a. 2014-2015)
- Brio Francesca (a.a. 2017-2018)
- Conto Camilla (a.a. 2017-2018)
- De Rossi Valentina (a.a. 2017-2018)
- Inglese Federica (a.a. 2017-2018)
- Ottonello Andrea (a.a. 2018-2019)
- Boccardo Valeria (a.a. 2019-2020)
- Ranotti Viola (a.a. 2019-2020)
- Sanmartino Valentina (a.a. 2019-2020)

**TECNICHE
ERBORISTICHE**

- Artiano Sabrina (a.a. 2008-2009)
- Ferrari Morgana (a.a. 2009-2010)
- Giordanino Michela (a.a. 2010-2011)
- Fantini Ilaria (a.a. 2011-2012)
- Ragazzo Alessandra (a.a. 2011-2012)
- Perrone Sara (a.a. 2011-2012)
- Oliveri Debora (a.a. 2013-2014)
- Allio Valentina (a.a. 2013-2014)
- Altamura Francesca (a.a. 2013-2014)
- Fogolin Alice (a.a. 2013-2014)

**SCIENZE degli ALIMENTI
e della NUTRIZIONE
UMANA**

TESI SPERIMENTALI:

- Ilaria Di Matteo (a.a. 2019-2020)

Relatore ad eventi scientifici di formazione ed aggiornamento professionale per Medici e Farmacisti

- 2008** Le variazioni funzionali indotte dalle sostanze ad azione stupefacente di origine vegetale: il punto di vista del farmacologo" - evento formativo ECM per Farmacisti 13/5 e 3/12 2008, Torino
- 2012** "Alimenti addizionati, funzionali, integrati: opportunità e criticità per l'alimentazione umana" - evento formativo ECM per Medici, Dietisti, Assistenti Sanitari SIAN 18/5/2012, Savigliano (CN)
- "Principi generali per un uso sicuro dei prodotti erboristici e cenni sui rischi di interazioni tra farmaci e sostanze naturali", 7 maggio 2012 (Cuneo) e 5 luglio 2012 (Alba).
- 2013** "Alimenti addizionati, funzionali, integrati: opportunità e criticità per l'alimentazione umana" - evento formativo ECM per Medici, Dietisti, Assistenti Sanitari SIAN 3/6/2013, Savigliano (CN)
- "Il dolore neuropatico: eziologia, sviluppo, deficit motori e la cura" – evento formativo ECM per Medici e Farmacisti – 9 ottobre 2013, Torino
- 2014** "Gli oppioidi nella terapia del dolore: efficacia, sicurezza ed appropriatezza prescrittiva" – evento formativo ECM per Farmacisti – 26/31 marzo 2014, Torino e 28 maggio, 1 dicembre 2014, Fossano (CN)
- "Le novità in farmacia: aspetti normativi e farmacologici", evento formativo ECM per Farmacisti – 13 novembre 2014, Torino
- "EX-OSP2 e Farmacia di Comunità: i necessari approfondimenti per dispensare consapevolmente medicinali innovativi", evento formativo ECM per Farmacisti – 13 novembre 2014, Torino
- 2015** "La farmacologia degli oppioidi: tra passato, presente e futuro per migliorare l'utilizzazione clinica degli analgesici oppioidi", evento formativo per Medici – 19 ottobre e 18 dicembre 2015, Torino
- 2016** "Le novità in Farmacia: aspetti normativi e farmacologici" evento formativo ECM per Farmacisti – 8/29 febbraio 2016, Torino e 14 marzo 2016, Fossano (CN)
- "Uso e Abuso dei farmaci nella persona anziana", evento divulgativo, Trino, 20-2-2016
- "Chemioterapici in Dermatologia: problemi e soluzioni", Evento formativo ECM per Medici – 5 maggio 2016, Riccione (RN)

“Il Dolore in fase acuta: le ultime novità sulle terapie farmacologiche”, Evento formativo ECM per Medici – 8 aprile 2016, Pianezza (TO).

“Il Dolore Neuropatico”, Evento formativo ECM per Medici – 12 maggio 2016, Caselle (TO); 18 maggio 2016, Torino.

“Parliamo di Farmaci in Pediatria”, Evento formativo ECM per Medici – 14 giugno 2016, 19 ottobre 2016, Torino.

“Emangiomi Infantili: Nuovi orizzonti”, Evento formativo ECM per Medici – 15 Settembre 2016, Riccione (RN)

“I paradossi degli oppioidi”, Evento formativo ECM per Medici – 18 Ottobre 2016, Humanitas Gradenigo, Torino

“Utilizzo della cannabis nel trattamento del dolore oncologico e altre terapie innovative”, Evento formativo ECM per Medici – 27-28 Settembre 2016, IRCC Candiolo, Torino

“Alimenti funzionali ed integrati: aggiornamenti in fitoalimurgia e sicurezza alimentare”, - evento formativo ECM per Medici, Dietisti, Assistenti Sanitari SIAN, 7 Ottobre 2016 Savigliano (CN)

“Il farmaco equivalente e l’aderenza alla terapia”, Workshop Regionale, 22 Ottobre 2016, Unione Industriali Torino

“Cannabis terapeutica: aspetti farmacologici, normativi e clinici” Convegno Regionale per Farmacisti e Medici, 17 Dicembre 2016, Torino

2017 “Le novità in farmacia: aspetti farmacologici”, convegno scientifico e formativo per Farmacisti – 20 febbraio 2017 e 2 marzo 2017 Torino; 15 marzo 2017 Fossano (CN)

“Gli analgesici oppioidi: tra presente e futuro”, convegno scientifico e formativo su “Dolore muscolo-scheletrico: dalla diagnosi alla terapia” per Medici e Farmacisti – 11 marzo 2017, Torino

“Trattamento del dolore in età evolutiva” convegno scientifico e formativo per Medici– 14 giugno 2017, Torino

“Nuovi approcci alla medicina di genere” convegno scientifico e formativo per Medici e Farmacisti – 23 settembre 2017, Torino

“Il percorso del paziente oncologico con dolore: dal medico di medicina generale allo specialista” convegno scientifico e formativo per Medici– 30 settembre 2017, Como

“Dolore e dolori” convegno scientifico e formativo per Medici– 30 novembre 2017, Torino

“Il dolore come problema riabilitativo” convegno scientifico e formativo per Medici– 21 ottobre 2017, Torino

“Tutte tigne? Dalla clinica alla diagnosi”, convegno scientifico e formativo per Medici 25 novembre 2017 Firenze

“Qualcosa di importante nel primo anno di vita”, convegno scientifico e formativo per Medici 11 novembre 2017, Torino

2018 “Medicina di Genere”, convegno scientifico e formativo per Medici e Farmacisti, 22 febbraio 2018, Torino

“Lesioni vascolari nel paziente pediatrico: il trattamento farmacologico dell'emangioma” convegno scientifico e formativo per Medici, 24 marzo 2018, Brescia

“Le novità in farmacia: aspetti farmacologici”, convegno scientifico e formativo per Farmacisti – 4 aprile 2018 Torino; 9 aprile 2018 Fossano (CN)

“Parkinson/Alzheimer: presa in carico del paziente politrattato”, convegno scientifico e formativo per Farmacisti – 9 maggio 2018 Torino; 13 giugno 2018 Fossano (CN)

“Cannabis ad uso medico: aspetti farmacologici, clinici e normativi”, convegno scientifico e formativo per Farmacisti – 19 aprile 2018 Torino

“Il dolore in pronto soccorso: quali novità e prospettive”, convegno scientifico e formativo per Medici – 12 ottobre 2018 Paderno Dugnano (MI)

“Il trattamento del dolore osteoarticolare e muscolare, acuto e cronico, nelle patologie degenerative muscoloscheletriche”, convegno scientifico e formativo per Medici – 24 novembre 2018 Aosta

2019 “Le novità in farmacia: aspetti farmacologici”, convegno scientifico e formativo per Farmacisti – 25 marzo 2019 Torino; 4 aprile 2019 Fossano (CN)

“Il dolore e il bambino: facciamo il punto con gli esperti” convegno scientifico e formativo per Medici – 23 maggio 2019 Torino

“Corso di formazione sul dolore nel paziente oncologico”, convegno scientifico e formativo per Medici 21 maggio 2019 Torino

“Fitopreparazioni: aspetti normativi, farmacologici e tossicologici”, convegno scientifico e formativo per Farmacisti – 21 settembre 2019 Fossano (CN)

“Corso di formazione sul low back pain”, convegno scientifico e formativo per Medici, 7 ottobre 2019 Torino

“Interazioni tra farmaci, piante medicinali ed alimentazione in cure palliative”, convegno scientifico e formativo per Medici– 26 novembre 2019 Torino; 26 novembre 2019

2020 “Osteoporosi e non solo” convegno scientifico e formativo per Medici– 22 gennaio 2020 Torino

“Antibiotico resistenza” webinar per Farmacisti– 3 Novembre 2020 Torino

“Micosi e dintorni: quali le molecole più attive”, webinar per Medici e Farmacisti online, 17 novembre 2020

2021 Oncogeriatrics - Modelli organizzativi di Geriatrics Sociale, convegno scientifico e formativo per Medici– 12 novembre 2021, Alba (CN)

ATTIVITA' DI RICERCA E PRODUZIONE SCIENTIFICA

Dal 2001 ad oggi, Autore di:

- 123 Pubblicazioni in extenso su riviste internazionali con Impact Factor
- 60 Proceedings su riviste internazionali con Impact Factor
- 1 Libro
- 4 Capitoli di libri

Tra le pubblicazioni, figurano articoli pubblicati su
Am J Resp Crit Care Med (IF 17.452)
Circulation Res (IF 14.467)
Pharmacology and Therapeutics (IF 10.557)
Annals of Surgery (IF 10.130)

- **Numero citazioni: 3683**
- **H index: 35**

(Scopus database 2-2-2022)

PRINCIPALI TEMI DI RICERCA AFFRONTATI

Gli interessi di ricerca, che si inseriscono nelle tematiche caratteristiche del settore scientifico- disciplinare BIO/14-Farmacologia, sono stati orientati alla identificazione del ruolo funzionale di specifici target recettoriali mediante l'uso di agonisti ed antagonisti selettivi in modelli sperimentali di infiammazione e di danno cerebro- e cardio-vascolare e/o metabolico.

In particolare, si possono identificare alcuni principali filoni tematici che vengono qui di seguito elencati:

➤ **Caratterizzazione farmacologica del ruolo dei neuropeptidi nel controllo dell'infiammazione neurogena**

Nell'ambito di questa linea di ricerca è stato studiato il ruolo delle tachichinine, in particolare della Sostanza P, nella modulazione del processo di attivazione ed infiltrazione granulocitaria, allo scopo di identificare meccanismi cellulari e biochimici che sottendono la comparsa ed evoluzione dell'infiammazione neurogena e che possono quindi essere suscettibili di modulazione farmacologica. L'utilizzo di agonisti e antagonisti selettivi alle differenti isoforme dei recettori delle tachichinine ha permesso di approfondire la caratterizzazione recettoriale degli effetti mediati dalla Sostanza P.

➤ **Identificazione di nuove strategie farmacologiche finalizzate alla protezione cerebro- e cardiovascolare *in vivo***

Nell'ambito di questa linea di ricerca sono stati sviluppati modelli *in vivo* di ischemia/riperfusion cerebrale, cardiaca, epatica e renale e modelli di danno multi-organo indotto da shock endotossico o emorragico. Mediante l'utilizzo di tali modelli sperimentali è stato possibile dimostrare gli effetti protettivi cardio- e cerebro-vascolari indotti dalla modulazione farmacologica di target recettoriali e vie di segnale coinvolti nella mediazione della risposta infiammatoria. In particolare, sono stati studiati gli effetti benefici conseguenti a somministrazioni di modulatori selettivi dei recettori PPAR, derivati dell'eritropoietina privi di attività ematopoietica, derivati eparinici privi di attività anticoagulante, inibitori selettivi delle vie di segnale Akt/GSK3-beta, NFkB, BTK e NLRP3 inflammasoma

➤ **Studio dei meccanismi patogenetici sottesi allo sviluppo di infiammazione metabolica ed effetti indotti dalla loro modulazione farmacologica**

Mediante l'utilizzo di modelli *in vivo* di disregolazione metabolica indotta dall'esposizione a diete ad alto contenuto calorico è stato possibile documentare il contributo di prodotti finali della glicazione avanzata (AGE) e di specifiche vie di segnale infiammatorio, in particolare la cascata dell'inflammasoma NLRP3, sullo sviluppo di infiammazione metabolica. Utilizzando tools farmacologici in grado di contrastare l'esacerbazione dell'infiammazione metabolica o implementare la risposta anti-infiammatoria endogena è stato possibile documentare una significativa riduzione delle alterazioni ormonali, glicidiche e lipidiche indotte da diete ipercaloriche. E' stata inoltre investigata la possibilità di riposizionamento terapeutico nell'ambito di patologie dismetaboliche di farmaci attualmente in uso clinico per altre indicazioni terapeutiche (es. inibitori BTK, inibitori JAK/STAT)

Attività Editoriale: Membro dell'Editorial Board delle seguenti riviste:

- **“Oxidative Medicine and Cellular Longevity”** (ISSN: 1942-0900; Electronic ISSN: 1942-0994; Journal Impact Factor 5.1)
- **“Frontiers in Immunology”** (ISSN and Electronic ISSN: 1664-3224; Journal Impact Factor 7.6, Associate Editor for the Section Inflammation)

- **“Frontiers in Endocrinology”** (ISSN and Electronic ISSN: 1664-2392 ; Journal Impact Factor 5.6, Associate Editor for the Section Cardiovascular Endocrinology)
- **“International Journal of Molecular Sciences”** (ISSN 1422-0067; Journal Impact Factor 4.5, Topic Editor of the section "Molecular Pharmacology")
- **"Journal of Diabetes & Metabolism"** (ISSN:2155-6156)
- **“Journal of Diabetes research and therapy”** (ISSN 2380-5544)
- **“Endocrinology & Metabolic Syndrome”** (ISSN 2161-1017)
- **“Diabetes Research” – Open Journal** (ISSN 2379-6375 online)

Lead Guest Editor for a Special Issue on the Journal "Mediators of Inflammation" (ISSN: 0962-9351), Title Special Issue: "Mediators of Interorgan Crosstalk in Metabolic Inflammation", 2013

Lead Guest Editor for a Special Issue on the Journal "Journal of Diabetes & Metabolism" (ISSN:2155-6156). Title Special Issue: "Diabetes, Obesity & their Related Diseases", J Diabetes Metab 2013, S11,

Guest Editor for a Special Issue on the Journal "BioMed Research International" (ISSN: 2314-6133). Title Special Issue: "Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Avenues", 2017

Guest Editor for a Special Issue on the Journal "Oxidative Medicine and Cellular Longevity" (ISSN: 1942-0900). Title Special Issue: Gut Microbiota and Oxidative Stress: Implications in Cardiovascular Disease, 2018

Attività di referee per numerose riviste internazionali, tra cui British Journal of Pharmacology; Biochemical Pharmacology; Journal of Pharmacology and Experimental Therapeutics; Diabetes; Expert Opinion in Pharmacotherapy; Free Radical Biology and Medicine; Pharmacology Biochemistry and Behavior; Shock; Stroke, etc.

Partecipazione a istituti di ricerca esteri di alta qualificazione:

Visiting Scientist presso il William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, University of London, London (UK) dal 09/2003 al 12/2004 (Congedo Straordinario per Motivi di Studio e Ricerca Scientifica - Decreto Rettorale n° 3311 del 23/07/2003)

Visiting Professor in Pharmacology at the Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel (Dozor Visiting Scholar), A.A. 2020-2021

Organizzazione di Congressi:

Membro dell'Organizing Committee dei seguenti Congressi:

- 8th Euro Global Diabetes Summit and Medicare Expo, November 3-5, 2015 at Valencia, Spain
- 10th European Diabetes Congress, July 14-16, 2016 at Cologne, Germany.
- International Conference on Nutrition, Health and Aging, September 26-28, 2018 at Frankfurt, Germany
- Euro Nutrition 2018, October 18-20, 2018 Paris, France
- "More than Neurons", November 29-December 1 2018, Torino
- "International Conference on Food Science and Nutrition" Oct 23-25 2019 Rome, Italy

Afferenza a Società Scientifiche Nazionali ed Internazionali:

- Società Italiana di Farmacologia
- Società Italiana di Ricerche Cardiovascolari
- British Society of Pharmacology
- European Society of Shock
- European Biomedical Research Association

Conseguimento di premi e riconoscimenti per l'attività scientifica:

Premio SAPIO 2005 per la Ricerca: "Aspetti patogenetici e farmacoterapeutici delle malattie neurodegenerative"

L'articolo Collino M et al., 2006 (Eur. J. Pharmacol., 530: 70-80, PMID: 16386242) è stato premiato come "top-cited research paper published in 2006" dalla rivista European Journal of Pharmacology

13th European Shock Society Congress 2009 (Lisbon, Portugal, 24-26 September): Travel Award per la migliore comunicazione orale

14th European Shock Society Congress 2011 (Taormina, Italy, August 31st September 2nd 2011): Travel Award per la migliore comunicazione orale

Vincitore della selezione europea per la partecipazione al workshop "Novel approaches to addressing genetic and environmental factors associated with diabetes and obesity" (5-8 July 2011, Rotorua, New Zealand) organizzato nell'ambito dell' European Commission's Seventh Framework Programme (FP7)

Beneficiario dell'incentivo una tantum a professori e ricercatori universitari dell'incentivo di cui all'art.29, comma 19 della legge 240/2010 secondo i criteri e le modalità definite dal decreto interministeriale n. 314/2011 e dal decreto ministeriale n.665/2013 (indicatore di impegno di ricerca) per l'anno 2018

Invited speaker and
chairperson

- 2006
- INVITED SPEAKER: "Drug therapy of headache." XII International Pain Clinic Congress, Turin (Italy), July 4-7, 2006
 - INVITED SPEAKER: "NSAIDs in cancer pain" XII International Pain Clinic Congress, Turin (Italy), July 4-7, 2006
- 2013
- INVITED CHAIRPERSON: Metabolism pharmacology - 36th Congress of the Italian Society of Pharmacology, 23rd-26th October 2013, Turin, Italy
- 2015
- INVITED SPEAKER: "Cardiometabolic diseases and the inflammasome: a key and innovative pharmacological target?" 8th Euro Global Diabetes Summit and Medicare Expo, Nov 3-5, 2015, Valencia, Spain
 - INVITED SPEAKER: "Alla scoperta di nuove relazioni tra nutrizione, microbiota e infiammazione: l'esempio dell'inflammasoma" Quarta Giornata Regionale di Nutrizione Clinica N 3 dicembre 2015, Pollenzo (CN)
 - INVITED SPEAKER: "Dalla ricerca di base alla clinica: possibile ruolo dell'inflammasoma e dei micro RNA nell' aterosclerosi" Società Italiana di Diabetologia, 20 febbraio 2015, Bologna
- 2016
- INVITED SPEAKER: "Chemioterapici in Dermatologia: problemi e soluzioni", XXV Congresso Nazionale AIDA (Associazione Italiana Dermatologi Ambulatoriali), 4-7 maggio 2016, Riccione (RN)
 - INVITED SPEAKER: "Emangiomi Infantili: Nuovi orizzonti", Congresso Nazionale SISAV (Società Italiana per lo Studio delle Anomalie Vascolari), 15-17 settembre 2016, Riccione (RN)
 - INVITED CHAIRPERSON: "More than neurons: toward a less neuronocentric view of brain disorders", 1-3 December 2016, Torino (Italy)
- 2018

2019

- INVITED SPEAKER: “Quali farmaci causano iperprolattinemia e perchè?” Congresso Nazionale della Società Italiana di Psichiatria, 13-17 ottobre 2018, Torino
- INVITED SPEAKER: “Terapia antimicotica: aspetti farmacologici” Congresso Nazionale ADOI (Associazione Dermatologi Ospedalieri Italiana), 17-20 ottobre 2018, Grosseto
- INVITED SPEAKER: “The form makes the difference: unrevealing the differential susceptibility to sugar-induced metabolic derangements evoked by liquid and solid fructose formulations” Euro Nutrition 2018, October 18-20, 2018 Paris, France
- INVITED SPEAKER: “Salivary Advanced Glycation End Products (AGEs) as novel biomarkers in evaluation of Risk factors for diet-related diseases: results from the European Network SALIVAGES” Euro Nutrition 2018, October 18-20, 2018 Paris, France
- INVITED CHAIRPERSON: “More than neurons: toward a less neuronocentric view of brain disorders”, December 1st 2018, Torino (Italy)
- INVITED SPEAKER: ““Innovative Technological Approaches for validation of Salivary AGEs as novel biomarkers in evaluation of risk factors in diet-related diseases” 8th International Congress on Nutrition & Medicine of the Future” May 18-18 2019 Cluj-Napoca, Romania.
- INVITED SPEAKER “Targeting metaflammation to counteract cardiometabolic diseases” National University of Ireland, Galway (NUI Galway), Sept 4th 2019
- INVITED SPEAKER “Farmaci biosimilari: principi farmacologici e loro implicazioni nella pratica clinica” Advisory Board sui farmaci biosimilari (Mylan Italia) Milano 10 ottobre 2019
- INVITED SPEAKER: “Innovative Technological Approaches for validation of Salivary AGEs as novel biomarkers in evaluation of risk factors in diet-related diseases” “International Conference on Food Science and Nutrition” Oct 23-25 2019 Rome, Italy
- INVITED CHAIRPERSON: 39th Congress of the Italian Society of Pharmacology, 20th-23rd November 2019, Florence, Italy

2021

- INVITED SPEAKER: “Pharmacological targeting of key proximal drivers of metaflammation in diet-induced metabolic diseases” *nell’ambito del Simposio* “New possible pharmacological targets for the treatment of eating disorders” 40th Congress of the Italian Society of Pharmacology, 9th-13rd March 2021
- INVITED CHAIRPERSON: 40th Congress of the Italian Society of Pharmacology, 9th-13rd March 2021
- INVITED SPEAKER: “Pharmacological targeting of key proximal drivers of metaflammation in diet-induced metabolic diseases” Scuola di Dottorato in Scienza del Farmaco, Dipartimento di

Farmacia, Università degli Studi di Napoli "Federico II", 8 ottobre 2021

- INVITED SPEAKER: "Slow drugs: the challenges of pharmacology in the elderly with cancer between present and future" Healthy Ageing Week 2021, Alba, November 8-13, 2021
- INVITED CHAIRPERSON: 1st meeting of the Immunopharmacology Working Group of the Italian Pharmacological Society, Perugia, November 24-26, 2021.

Collaborazioni
scientifiche nazionali

Prof. Aragno Manuela
Università di Torino

Prof. Cifani Carlo
Università di Camerino

Prof. Cordero Chiara Emilia
Università di Torino

Prof. Eva Carola
Università di Torino

Prof. Masini Emanuela
Università di Firenze

Prof. Minetto Marco
Università di Torino

Prof. Montagnani Monica
Università di Bari

Prof. Parola Maurizio
Università di Torino

Prof. Pagliaro Pasquale
Università di Torino

Prof. Squadrito Francesco
Università di Messina

Prof. Tuohy Kieran
Edmund Mach Foundation, San Michele all'Adige, Italy.

Prof. Vairetti Mariapia
Università di Pavia

Collaborazioni
scientifiche internazionali

Prof. Thiemermann Chris

William Harvey Research Institute, Queen Mary's School of Medicine and Dentistry, University of London (UK)

Prof. Ryffel Bernhard

University of Orleans and Centre National de la Recherche Scientifique, France

Dott. Cerami Anthony

Araim Pharmaceuticals, Tarrytown, NY, USA

Prof Coldewey Sina

Jena University Hospital, Germany

Prof. Martin Lukas

University Hospital Aachen, Germany

Prof. Aranka Ilea

University of Medicine and Pharmacy Iuliu Hatieganu Cluj, Romania

Prof. Sainz Rosa M.

University of Oviedo, Spain

Prof. Joshi Lokesh

National University of Ireland Galway, Ireland

Prof. Henle Thomas

Technische Universitaet Dresden, Germany

Prof. Landberg Rikard

Chalmers University of Technology, Sweden

Prof. Frank Jan

University of Hohenheim, Germany

Prof. Patrono Cesare

Karolinska Institutet, Sweden

Responsabilita'
scientifica per progetti di
ricerca:

- **Coordinatore del Progetto Europeo** "Innovative Technological Approaches for validation of Salivary AGEs as novel biomarkers in evaluation of risk factors for diet-related diseases", ERA-HDHL Transnational Call "Biomarkers for Nutrition and Health", 2017-2020 (1.086.653 euro)
- **Principal Investigator del Progetto Europeo** "Correlations between biomarkers and microbiota" ERA-HDHL Call for an European Knowledge Platform on Food, Diet, Intestinal Microbiomics and Human Health 2019-2021 (24.000 euro)

- **Principal Investigator del Progetto Europeo** “Tailored Carbohydrate Quality for Personalized Weight Management and Metabolic Health”, HDHL-INTIMIC JPI Call “Impact of Diet, Food Components and Food Processing on Body Weight Regulation and Overweight Related Metabolic Diseases”, 2020-2023 (1.100.000 euro)
- **Responsabile Scientifico per l'Università di Torino del programma di mobilità internazionale Erasmus Plus** fellowship programme, Bando Erasmus+ call 2017 (Università partner: Ben-Gurion University of the Negev, Israel 2017-2020; Grant Agreement Number 2017-1-IT02-KA107-036256).
- **Responsabile Scientifico per l'Università di Torino del programma di mobilità internazionale Marie Curie action** WHRI-ACADEMY fellowship programme (Marie Curie action of the 7th Framework Programme of the European Commission, 2014-2016)
- **Responsabile dello studio** “Scaffale Patologie Croniche” affidato da Federfarma Piemonte (anno 2016)
- **Responsabile del progetto di ricerca** "BTK inhibitors as pharmacological tools for diet-induced metabolic diseases" affidato da William Harvey Research Limited, London (UK) (anno 2016)
- **Responsabile di progetti di Ricerca Locale** Finanziata dall'Università di Torino, Ex-60% dall'anno 2013 ad oggi.
- **Responsabile Progetto di Ricerca** “Nuovi approcci farmacologici per il danno cardiometabolico: studio preliminare di effetti protettivi di nuovi inibitori dell'inflammasoma NLRP3 in un modello di danno ischemico cardiaco” finanziata dall'Università di Torino anno 2015 – Linea B.
- **Partner del progetto di ricerca nazionale PRIN 2007** "Sindrome metabolica come fattore di rischio per l'ischemia/riperfusion: fasi sperimentali per nuove strategie terapeutiche contro il danno da infiammazione e da stress ossidativo"
- **Partner del progetto di ricerca nazionale PRIN 2004** "Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma coloretale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi"

- **Partner del progetto di ricerca nazionale PRIN 2000** "Stress ossidativo in modelli di patologie degenerative: nuovi derivati di sintesi fenolici, benzilaminici e taurinoidi come potenziali agenti citoprotettivi"
- **Partner del progetto di ricerca regionale** "Studio di fattori che influenzano la trasformazione dell'epitelio del colon in epitelio adenomatoso" (Bando Regione Piemonte per progetti di ricerca sanitaria finalizzata 2002, Componente Unità di Ricerca)
- **Partner del progetto di ricerca regionale** "Diabete come fattore di rischio per l'insufficienza renale acuta: valutazione di efficacia di nuove terapie in modelli sperimentali" (Bando Regione Piemonte per progetti di ricerca sanitaria finalizzata 2008, Componente Unità di Ricerca)
- **Partner del progetto di ricerca regionale** "Sindrome metabolica e rischio di ischemia renale: potenzialità terapeutiche di agonisti selettivi dei recettori PPARbeta/delta" (Bando Regione Piemonte per progetti di ricerca sanitaria finalizzata 2009, Componente Unità di Ricerca)

ALLEGATI

- Elenco delle pubblicazioni scientifiche

DICHIARAZIONE SOSTITUTIVA DI CERTIFICAZIONE E ATTO DI NOTORIETA'

(ai sensi degli artt. 46, 47 e 48 del D.P.R. 28/12/2000, n. 445)

Il sottoscritto Massimo COLLINO **DICHIARA** che quanto contenuto nel curriculum scientifico e didattico sopra riportato è corrispondente al vero. Dichiaro inoltre di essere in possesso di tutti i titoli in esso riportati.

Il sottoscritto, infine, esprime il proprio consenso affinché i dati personali forniti possano essere trattati, nel rispetto del D. Lgs. n.196/2003, per gli adempimenti previsti

Massimo Collino

Torino, 23 MARZO 2021



ALLEGATO
ELENCO PUBBLICAZIONI SCIENTIFICHE

PUBBLICAZIONI IN EXTENSO

1. Dianzani C, Lombardi G, **Collino M**, Ferrara C, Cassone MC, Fantozzi R. Priming effects of substance P on calcium changes evoked by interleukin-8 in human neutrophils. J Leukoc Biol. 69:1013-1018, 2001
2. Dianzani C., **Collino M.**, Lombardi G., Garbarino G., Fantozzi R. Substance P increases neutrophil adhesion to human umbilical vein endothelial cells. Br. J. Pharmacol., 139: 1103-1110, 2003.

3. Collin M., Rossi A., Cuzzocrea S., Patel NSA., Di Paola R., Hadley J., **Collino M**, Sautebin L., Thiernemann C. Reduction of the multiple organ injury and dysfunction caused by endotoxemia in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton. *J. Leukoc. Biol.* 76: 961-970, 2004.
4. **Collino M**, Patel NS, Lawrence KM, Collin M, Latchman DS, Yaqoob MM, Thiernemann C. The selective PPAR γ antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. *Kidney Int.*, 68: 529-536, 2005.
5. **Collino M**, Aragno M, Mastrocola R, Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiernemann C, Fantozzi R. Modulation of the oxidative stress and inflammatory response by peroxisome proliferator-activated receptor- γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. *Eur. J. Pharmacol.*, 530: 70-80, 2006.
This paper was awarded by European Journal of Pharmacology as “top-cited research paper published in 2006”.
6. Gallicchio M, Rosa AC, Benetti E, **Collino M**, Dianzani C, Fantozzi R. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells. *Brit. J. Pharmacol.*, 147:681-689, 2006.
7. Dianzani C; **Collino M**; Gallicchio M; Samaritani S; Signore G; Menicagli R; Fantozzi R Evaluation of in vitro anti-inflammatory activity of some 2-alkyl-4,6-dimethoxy-1,3,5- triazines. *J. Pharm. Pharmacol.*, 58: 219-226, 2006
8. Dianzani C*, **Collino M***, Gallicchio M, Di Braccio M, Roma G, Fantozzi R Effects of anti-inflammatory [1,2,4]triazolo[4,3-a] [1,8]naphthyridine derivatives on human stimulated PMN and endothelial cells: an in vitro study. *J. Inflamm.*, 3: 4-15, 2006. *
***C. Dianzani and M. Collino are shared first authors of this study.**
9. **Collino M**, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiernemann C, Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. *Free Radic Biol Med.* 41:579-589, 2006
10. Patel NS, Cuzzocrea S, **Collino M**, Chatterjee PK, Mazzon E, Britti D, Yaqoob MM, Thiernemann C. The role of cyclooxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. *Eur J Pharmacol.* 562: 148-154, 2007
11. Gallicchio M, Rosa AC, Dianzani C, Brucato L, Benetti E, **Collino M**, Fantozzi R. Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29). *Br J Pharmacol.* 2008;153(5):870-8.
12. Dianzani C, Brucato L, Gallicchio M, Rosa AC, **Collino M**, Fantozzi R. Celecoxib modulates adhesion of HT29 colon cancer cells to vascular endothelial cells by inhibiting ICAM-1 and VCAM-1 expression. *Br J Pharmacol.* 2008;153:1153-61.

13. Murch O, Abdelrahman M, **Collino M**, Gallicchio M, Benetti E, Mazzon E, Fantozzi R, Cuzzocrea S, Thiernemann C. Sphingosylphosphorylcholine reduces the organ injury/dysfunction and inflammation caused by endotoxemia in the rat. *Crit Care Med*. 2008; 36:550-9
14. **Collino M**, Thiernemann C, Mastrocola R, Gallicchio M, Benetti E, Miglio G, Castiglia S, Danni O, Murch O, Dianzani C, Aragno M, Fantozzi R. Treatment with the glycogen synthase kinase-3 β inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus. *Shock*. 2008; 30:299-307.
15. **Collino M**, Patel NS, Thiernemann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury. *Therapeutic Advances in Cardiovascular Disease*, 2008; 2:179-197
16. Tripatara P, Patel NS, **Collino M**, Gallicchio M, Kieswich J, Castiglia S, Benetti E, Stewart KN, Brown PA, Yaqoob MM, Fantozzi R, Thiernemann C. Generation of Endogenous Hydrogen Sulfide by Cystathionine Gamma-Lyase limits the Renal Injury and Dysfunction caused by Ischemia/Reperfusion. *Lab Invest*. 2008; 88:1038-48.
17. Sivarajah A, **Collino M**, Yasin M, Benetti E, Gallicchio M, Mazzon E, Cuzzocrea S, Fantozzi R, Thiernemann C. Anti-apoptotic and anti-inflammatory effects of hydrogen sulphide in a rat model of regional myocardial ischaemia and reperfusion” *Shock*, 2009;31:267-74.
18. **Collino M**, Aragno M, Castiglia S, Tomasinelli C, Thiernemann C, Boccuzzi G, Fantozzi R. Insulin reduces cerebral ischemia/reperfusion injury in the hippocampus of diabetic rats: a role for glycogen synthase kinase-3beta. *Diabetes*. 2009; 58:235-42.
19. Miglio G, Rosa AC, Rattazzi L, **Collino M**, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. *Neurochem Int*. 2009;55:496-504.
20. Aragno M, Tomasinelli CE, Vercellinato I, Catalano MG, **Collino M**, Fantozzi R, Danni O, Boccuzzi G. SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. *Free Radic Biol Med*. 2009;47:1067-74.
21. **Collino M**, Castiglia S, Manoni M, Salsini L., Chini J., Masini E., Fantozzi R. Effects of a semi-synthetic N-,O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischemia/reperfusion injury. *Thromb Haemost*. 2009;102:837-45.
22. Kapoor A, **Collino M**, Castiglia S, Fantozzi R, Thiernemann C. Activation of Peroxisome Proliferator-Activated Receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat. *Shock*. 2010;34:117-124.
23. **Collino M**, Aragno M, Castiglia S, Miglio G, Tomasinelli C, Boccuzzi G, Thiernemann C, Fantozzi R. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. *Br J Pharmacol*. 2010; 160:1892-902.
This paper was highlighted by British Journal of Pharmacology with a commentary (Chatterjee PK., Hepatic inflammation and insulin resistance in pre-diabetes - further evidence for the beneficial actions of PPAR-gamma agonists and a role for SOCS-3 modulation. Br J Pharmacol. 2010;160:1889-1891)

24. Kapoor A, Shintani Y, **Collino M**, Osuchowski MF, Busch D, Patel NS, Sepodes B, Castiglia S, Fantozzi R, Bishop-Bailey D, Mota-Filipe H, Yaqoob MM, Suzuki K, Bahrami S, Désvergne B, Mitchell JA, Thiernemann C. Protective role of peroxisome proliferator-activated receptor- β/δ in septic shock. *American Journal of Respiratory and Critical Care Medicine*. 2010; 182:1506-1515.
25. Lovell MJ, Yasin M, Lee KL, Cheung KK, Shintani Y, **Collino M**, Sivarajah A, Leung KY, Takahashi K, Kapoor A, Yaqoob MM, Suzuki K, Lythgoe MF, Martin J, Munroe PB, Thiernemann C, Mathur A. Bone marrow mononuclear cells reduce myocardial reperfusion injury by activating the PI3K/Akt survival pathway. *Atherosclerosis*. 2010; 213:67-76
26. Miglio G, Rosa AC, Rattazzi L, Grange C, **Collino M**, Camussi G, Fantozzi R The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury. *Br J Pharmacol*. 2011;162:111-125.
27. **Collino M**, Benetti E, Miglio G, Castiglia S, Rosa AC, Aragno M, Thiernemann C, Fantozzi R. Peroxisome proliferator-activated receptor β/δ agonism protects the kidney against ischemia/reperfusion injury in diabetic rats. *Free Radic Biol Med*. 2011; 50:345-353
28. Patel NS, Nandra KK, Brines M, **Collino M**, Wong WS, Kapoor A, Benetti E, Goh FY, Fantozzi R, Cerami A, Thiernemann C. A non-erythropoietic peptide that mimicks the 3D structure of erythropoietin reduces organ injury/dysfunction and inflammation in experimental hemorrhagic shock. *Mol Med*. 2011 May 13. doi: 10.2119/molmed.2011.00053.
29. Benetti E, Patel NS, **Collino M**. The Role of PPAR β/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications. *Endocr Metab Immune Disord Drug Targets*. 2011;11:273-84.
30. Patel NS, **Collino M**, Yaqoob MM, Thiernemann C. Erythropoietin in the intensive care unit: beyond treatment of anemia. *Ann Intensive Care*. 2011;1:40.
31. Rosa AC, Rattazzi L, Miglio G, **Collino M**, Fantozzi R. Angiotensin II induces tumor necrosis factor- α expression and release from cultured human podocytes *Inflamm Res*. 2012;61:311-317.
32. Nandra KK, Takahashi K, **Collino M**, Benetti E, Wong WS, Goh FY, Suzuki K, Patel NS, Thiernemann C. Acute treatment with bone marrow-derived mononuclear cells attenuates the organ injury/dysfunction induced by hemorrhagic shock in the rat. *Shock*. 2012;37:592-598
33. Patel NS, Kerr-Peterson HL, Brines M, **Collino M**, Rogazzo M, Fantozzi R, Wood EG, Johnson FL, Yaqoob MM, Cerami A, Thiernemann C. Delayed Administration of Pyroglutamate Helix B Surface Peptide (pHBSP), a Novel Nonerythropoietic Analog of Erythropoietin, Attenuates Acute Kidney Injury. *Mol Med*. 2012;18:719-727.
34. **Collino M**, Pini A., Mastroianni R., Benetti E., Lanzi C., Bani D., Chini J., Manoni M., Fantozzi R., Masini E. The non-anticoagulant heparin-like K5 polysaccharide derivative K5-N,OSepi attenuates myocardial ischaemia/reperfusion injury. *J Cell Mol Med* 2012; 16: 2196-2207.
35. Bertinaria M, Rolando B, Giorgis M, Montanaro G, Marini E, **Collino M**, Benetti E, Daniele PG, Fruttero R, Gasco A. Carnosine analogues containing NO-donor substructures: synthesis,

- physico-chemical characterization and preliminary pharmacological profile. *Eur J Med Chem.* 2012;54:103-12.
36. Rosa AC, Grange C, Pini A, Katebe MA, Benetti E, **Collino M**, Miglio G, Bani D, Camussi G, Chazot PL, Fantozzi R. Overexpression of histamine H4 receptors in the kidney of diabetic rats. *Inflamm Res* 2013; 62:357-365.
 37. **Collino M**, Benetti E, Rogazzo M, Mastrocola R, Yaqoob MY, Aragno M, Thiemermann C, Fantozzi R. (2012). Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR- agonism correlates with impaired NLRP3 inflammasome activation. *Biochem Pharmacol.* 2013;85:257-264
 38. Nandra KK, **Collino M**, Rogazzo M, Fantozzi R, Patel NS, Thiemermann C. Pharmacological preconditioning with erythropoietin attenuates the organ injury and dysfunction induced in a rat model of hemorrhagic shock. *Dis Model Mech.* 2013;6:701-709.
 39. Bangash MN, Patel NS, Benetti E, **Collino M**, Hinds CJ, Thiemermann C, Pearse RM. Dopexamine can attenuate the inflammatory response and protect against organ injury in the absence of significant effects on hemodynamics or regional microvascular flow. *Crit Care.* 2013;17(2):R57
 40. Khan AI, Coldewey SM, Patel NS, Rogazzo M, **Collino M**, Yaqoob MM, Radermacher P, Kapoor A, Thiemermann C. Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β -common receptor. *Dis Model Mech.* 2013;6(4):1021-1030.
 41. Coldewey SM, Rogazzo M, **Collino M**, Patel NS, Thiemermann C. Inhibition of I κ B kinase reduces the multiple organ dysfunction caused by sepsis in the mouse. *Dis Model Mech.* 2013;6(4):1031-1042.
 42. **Collino M**, Pini A, Mugelli N, Mastroianni R, Bani D, Fantozzi R, Papucci L, Fazi M, Masini E. Beneficial effect of prolonged heme oxygenase 1 activation in a rat model of chronic heart failure. *Dis Model Mech.* 2013;6(4):1012-1020.
 43. Coldewey SM, Khan AI, Kapoor A, **Collino M**, Rogazzo M, Brines M, Cerami A, Hall P, Sheaff M, Kieswich JE, Yaqoob MM, Patel NS, Thiemermann C. Erythropoietin attenuates acute kidney dysfunction in murine experimental sepsis by activation of the β -common receptor. *Kidney Int.* 2013;84(3):482-90.
This paper was highlighted by Kidney International with a commentary (Masaomi Nangaku. Tissue protection by erythropoietin: new findings in a moving field. Kidney International 2013 84:427–429)
 44. Benetti E, Chiazza F, Patel NS, **Collino M**. The NLRP3 Inflammasome as a Novel Player of the Intercellular Crosstalk in Metabolic Disorders. *Mediators Inflamm.* 2013;2013:678627. doi: 10.1155/2013/678627.
 45. Benetti E, Mastrocola R, Rogazzo M, Chiazza F, Aragno M, Fantozzi R, **Collino M***, Minetto MA*. High Sugar Intake and Development of Skeletal Muscle Insulin Resistance and Inflammation in Mice: A Protective Role for PPAR- δ Agonism. *Mediators Inflamm.* 2013;2013:509502. doi: 10.1155/2013/509502.

46. ***Collino and Minetto are co-last authors**

47. **Collino M**, Rogazzo M, Pini A, Benetti E, Rosa AC, Chiazza F, Fantozzi R, Bani D, Masini E. Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. *J Cell Mol Med.* 2013;17:1494-1505.
48. Mastrocola R, **Collino M**, Rogazzo M, Medana C, Nigro D, Boccuzzi G, Aragno M. Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice. *Am J Physiol Gastrointest Liver Physiol.* 2013;305:G398-G407.
49. **Collino M**, Rudich A, Konrad D. Mediators of interorgan crosstalk in metabolic inflammation. *Mediators Inflamm.* 2013; 2013:609096.
50. Chen J, Chiazza F, **Collino M**; Patel NSA, Coldewey SM, Thiemermann C. Gender dimorphism of the cardiac dysfunction in murine sepsis: Signalling mechanisms and age-dependency. *PlosOne.* 2014;9(6):e100631.
51. **Collino M**, Mastrocola R, Nigro D, Chiazza F, Aragno M, D'Antona G, Minetto MA. Variability in myosteatosis and insulin resistance induced by high-fat diet in mouse skeletal muscles. *Biomed Res Int.* 2014; 2014:569623.
52. **Collino M**, Benetti E, Rogazzo M, Chiazza F, Mastrocola R, Nigro D, Cutrin JC, Aragno M, Fantozzi R, Minetto MA, Thiemermann C. A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. *Br J Pharmacol.* 2014 Dec;171(24):5802-15.
53. Bressanello D, Liberto E, **Collino M**, Reichenbach SE, Benetti E, Chiazza F, Bicchi C, Cordero C. Urinary metabolic fingerprinting of mice with diet-induced metabolic derangements by parallel dual secondary column-dual detection two-dimensional comprehensive gas chromatography. *J Chromatogr A.* 2014 Sep 26;1361:265-76.
54. Chiazza F, Chegaev K, Rogazzo M, Cutrin JC, Benetti E, Lazzarato L, Fruttero R, **Collino M**. A nitric oxide-donor furoxan moiety improves the efficacy of edaravone against early renal dysfunction and injury evoked by ischemia/reperfusion. *Oxid Med Cell Longev.* 2015; 2015:804659.
55. Sordi R, Chiazza F, Patel NS, Doyle RA, **Collino M**, Thiemermann C. 'Preconditioning' with low dose lipopolysaccharide aggravates the organ injury/dysfunction caused by hemorrhagic shock in rats. *PLoS One.* 2015; 10(4):e0122096.
56. Mastrocola R, **Collino M**, Nigro D, Chiazza F, D'Antona G, Aragno M, Minetto MA. Accumulation of advanced glycation end-products and activation of the SCAP/SREBP lipogenetic pathway occur in diet-induced obese mouse skeletal muscle. *PLoS One.* 2015; 10(3):e0119587.
57. **Collino M**, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. *Pharmacol Ther.* 2015; 151:32-40. doi: 10.1016/j.pharmthera.2015.02.005.

58. Sordi R, Chiazza F, Johnson FL, Patel NS, Brohi K, **Collino M**, Thiernemann C. Inhibition of I κ B Kinase Attenuates the Organ Injury and Dysfunction Associated With Hemorrhagic Shock. *Mol Med*. 2015;21(1):563-75.
59. Chiazza F, Couturier-Maillard A, Benetti E, Mastrocola R, Nigro D, Cutrin JC, Serpe L, Aragno M, Fantozzi R, Ryffel B, Thiernemann C, **Collino M**. Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice. *Mol Med*. 2015; 21(1):1025-1037. doi: 10.2119/molmed.2015.00104.
60. Mastrocola R, Nigro D, Chiazza F, Medana C, Dal Bello F, Boccuzzi G, **Collino M**, Aragno M. Fructose-derived advanced glycation end-products drive lipogenesis and skeletal muscle reprogramming via SREBP-1c dysregulation in mice. *Free Radic Biol Med*. 2016; 91:224-35
61. Mastrocola R, **Collino M**, Penna C, Nigro D, Chiazza F, Fracasso V, Tullio F, Alloatti G, Pagliaro P, Aragno M. Maladaptive Modulations of NLRP3 Inflammasome and Cardioprotective Pathways Are Involved in Diet-Induced Exacerbation of Myocardial Ischemia/Reperfusion Injury in Mice. *Oxid Med Cell Longev*. 2016; 2016:3480637. doi: 10.1155/2016/3480637
62. Mastrocola R, Nigro D, Cento AS, Chiazza F, **Collino M**, Aragno M. High-fructose intake as risk factor for neurodegeneration: Key role for carboxy methyllysine accumulation in mice hippocampal neurons. *Neurobiol Dis*. 2016; 89:65-75. doi: 10.1016/j.nbd.2016.02.005.
63. Sordi R, Chiazza F, **Collino M**, Assreuy J, Thiernemann C. Neuronal Nitric Oxide Synthase is Involved in Vascular Hyporeactivity and Multiple Organ Dysfunction Associated with Haemorrhagic Shock. 2016 May;45(5):525-33.
64. Coldewey SM, Benetti E, **Collino M**, Pfeilschifter J, Sponholz C, Bauer M, Huwiler A, Thiernemann Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. *Sci Rep*. 2016 Jun 9;6:27594. doi: 10.1038/srep27594.
65. Benetti E, Mastrocola R, Vitarelli G, Cutrin JC, Nigro D, Chiazza F, Mayoux E, **Collino M**, Fantozzi R. Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation. *J Pharmacol Exp Ther*. 2016;359(1):45-53.
66. Mastrocola R, Penna C, Tullio F, Femminò S, Nigro D, Chiazza F, Serpe L, Collotta D, Alloatti G, Cocco M, Bertinaria M, Pagliaro P, Aragno M, **Collino M**. Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways. *Oxid Med Cell Longev*. 2016; 2016:5271251. doi: 10.1155/2016/5271251.
67. Martin L, Horst K, Chiazza F, Oggero S, **Collino M**, Brandenburg K, Hildebrand F, Marx G, Thiernemann C, Schuerholz T. The synthetic antimicrobial peptide 19-2.5 attenuates septic cardiomyopathy and prevents down-regulation of SERCA2 in polymicrobial sepsis. *Sci Rep*. 2016 Nov 17; 6:37277. doi: 10.1038/srep37277.
68. Sordi R, Nandra KK, Chiazza F, Johnson FL, Cabrera CP, Torrance HD, Yamada N, Patel NS, Barnes MR, Brohi K, **Collino M**, Thiernemann C. Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation. *Ann Surg*. 2017 Feb;265(2):408-417. doi: 10.1097/SLA.0000000000001664.

69. Chen J, Kieswich JE, Chiazza F, Moyes AJ, Gobbetti T, Purvis GS, Salvatori DC, Patel NS, Perretti M, Hobbs AJ, **Collino M**, Yaqoob MM, Thiernemann C. I κ B Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD. *J Am Soc Nephrol*. 2017 Jan;28(1):94-105. doi: 10.1681/ASN.2015060670.
70. Nigro D, Menotti F, Cento AS, Serpe L, Chiazza F, Dal Bello F, Romaniello F, Medana C, **Collino M**, Aragno M, Mastrocola R. Chronic administration of saturated fats and fructose differently affect SREBP activity resulting in different modulation of Nrf2 and Nlrp3 inflammasome pathways in mice liver. *J Nutr Biochem*. 2017 Jan 28;42:160-171. doi: 10.1016/j.jnutbio.2017.01.010.
71. Potenza MA, Nacci C, De Salvia MA, Sgarra L, **Collino M**, Montagnani M. Targeting endothelial metaflammation to counteract diabetes cardiovascular risk: Current and perspective therapeutic options. *Pharmacol Res*. 2017 Jun;120:226-241. doi: 10.1016/j.phrs.2017.04.009.
72. Johnson FL, Patel NSA, Purvis GSD, Chiazza F, Chen J, Sordi R, Hache G, Merezhko VV, **Collino M**, Yaqoob MM, Thiernemann C. Inhibition of I κ B Kinase at 24 Hours After Acute Kidney Injury Improves Recovery of Renal Function and Attenuates Fibrosis. *J Am Heart Assoc*. 2017 Jul 3;6(7). pii: e005092. doi: 10.1161/JAHA.116.005092.
73. Chiazza F, Cento AS, Collotta D, Nigro D, Rosa G, Baratta F, Bitonto V, Cutrin JC, Aragno M, Mastrocola R, **Collino M**. Protective Effects of Pyridoxamine Supplementation in the Early Stages of Diet-Induced Kidney Dysfunction. *Biomed Res Int*. 2017;2017:2682861. doi: 10.1155/2017/2682861.
74. Oltean, S; Coward, R; **Collino, M** ; Baelde, H. Diabetic Nephropathy: Novel Molecular Mechanisms and Therapeutic Avenues. *Biomed Res Int*. 2017;2017: 3146524 DOI: 10.1155/2017/3146524
75. Cannito S, Morello E, Bocca C, Foglia B, Benetti E, Novo E, Chiazza F, Rogazzo M, Fantozzi R, Povero D, Sutti S, Bugianesi E, Feldstein AE, Albano E, **Collino M**, Parola M. Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis. *PLoS One*. 2017 Mar 1;12(3):e0172575. doi: 10.1371/journal.pone.0172575.
This paper was awarded by PlosOne as one of the top 10% most cited PLOS ONE papers published in 2017.
76. Purvis GSD, Chiazza F, Chen J, Azevedo-Loiola R, Martin L, Kusters DHM, Reutelingsperger C, Fountoulakis N, Gnudi L, Yaqoob MM, **Collino M**, Thiernemann C, Solito E. Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes. *Diabetologia*. 2018 Feb;61(2):482-495. doi: 10.1007/s00125-017-4469-y. Epub 2017 Oct 30.
77. Spallotta F, Cencioni C, Atlante S, Garella D, Cocco M, Mori M, Mastrocola R, Kuenne C, Guenther S, Nanni S, Azzimato V, Zukunft S, Kornberger A, Sürün D, Schnütgen F, von Melchner H, Di Stilo A, Aragno M, Braspenning M, van Criekinge W, De Blasio MJ, Ritchie RH, Zaccagnini G, Martelli F, Farsetti A, Fleming I, Braun T, Beiras-Fernandez A, Botta B, **Collino M**, Bertinaria M, Zeiher AM, Gaetano C. Stable Oxidative Cytosine Modifications Accumulate in Cardiac

Mesenchymal Cells From Type2 Diabetes Patients: Rescue by α -Ketoglutarate and TET-TDG Functional Reactivation. *Circ Res.* 2018 5;122(1):31-46. doi: 10.1161/CIRCRESAHA.117.311300.

78. Bitto A, Irrera N, Pizzino G, Pallio G, Mannino F, Vaccaro M, Arcoraci V, Aliquò F, Minutoli L, Colonna MR, Galeano MR, Brines M, De Ponte C, **Collino M**, Squadrito F, Altavilla D. Activation of the EPOR- β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes. *Biochim Biophys Acta.* 2018 Feb;1864(2):632-639. doi: 10.1016/j.bbadis.2017.12.006.

79. Benetti E, Mastrocola R, Chiazza F, Nigro D, D'Antona G, Bordano V, Fantozzi R, Aragno M, **Collino M***, Minetto MA*. Effects of vitamin D on insulin resistance and myosteatosis in diet-induced obese mice. *PLoS One.* 2018 Jan 17;13(1):e0189707. doi: 10.1371/journal.pone.0189707

* **Collino and Minetto are co-last authors**

This paper was awarded by PlosOne as one of the top 10% most cited PLOS ONE papers published in 2018.

80. Bressanello D, Liberto E, **Collino M**, Chiazza F, Mastrocola R, Reichenbach SE, Bicchi C, Cordero C. Combined untargeted and targeted fingerprinting by comprehensive two-dimensional gas chromatography: revealing fructose-induced changes in mice urinary metabolic signatures. *Anal Bioanal Chem.* 2018 Mar 7. doi: 10.1007/s00216-018-0950-9.

81. Mastrocola R, Ferrocino I, Liberto E, Chiazza F, Cento AS, Collotta D, Querio G, Nigro D, Bitonto V, Cutrin JC, Rantsiou K, Durante M, Masini E, Aragno M, Cordero C, Cocolin L, **Collino M**. Fructose liquid and solid formulations differently affect gut integrity, microbiota composition and related liver toxicity: a comparative in vivo study. *J Nutr Biochem.* 2018 Feb 13;55:185-199. doi: 10.1016/j.jnutbio.2018.02.003

82. Chiazza F, Tammen H, Pintana H, Lietzau G, **Collino M**, Nyström T, Klein T, Darsalia V, Patrone C. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1 α /CXCR4 pathway. *Cardiovasc Diabetol.* 2018 May 19;17(1):60. doi: 10.1186/s12933-018-0702-3

83. Aswani A-, Manson J, Itagaki K, Chiazza F, **Collino M**, Wupeng W. L-, Chan T. K., Wong W. S. F., Hauser C. J., Thiemermann C., Brohi K.. Scavenging Circulating Mitochondrial DNA as a Potential Therapeutic Option for Multiple Organ Dysfunction in Trauma Hemorrhage. *Frontiers in Immunology* 2018; 9:891-910. doi: 10.3389/fimmu.2018.00891

84. Ilea A, Băbțan AM, Boșca BA, Crișan M, Petrescu NB, **Collino M**, Sainz RM, Gerlach JQ, Câmpian RS. Advanced glycation end products (AGEs) in oral pathology. *Arch Oral Biol.* 2018 May 18;93:22-30. doi: 10.1016/j.archoralbio.2018.05.013.

85. Yamada N, Martin LB, Zechendorf E, Purvis GS, Chiazza F, Varrone B, **Collino M**, Shepherd J, Heinbockel L, Gutschmann T, Correa W, Brandenburg K, Marx G, Schuerholz T, Brohi K, Thiemermann C. Novel Synthetic, Host-defense Peptide Protects Against Organ Injury/Dysfunction in a Rat Model of Severe Hemorrhagic Shock. *Ann Surg.* 2018 268(2):348-356

86. Khan AI, Kapoor A, Che J, Martin L, Rogazzo M, Mercier T, Decosterd L, **Collino M**, Thiemermann C. The Anti-Malarial Drug Artesunate Attenuates Cardiac Injury in a Rodent Model of Myocardial Infarction. *Shock*. 2018;49(6):675-681
87. Mastrocola R, Aragno M, Alloatti G, **Collino M**, Penna C, Pagliaro P. Metaflammation: tissue-specific alterations of the NLRP3 inflammasome platform. *Curr Med Chem*. 2018;25(11):1294-1310
88. Collotta D, Lucarini L, Chiazza F, Cento AS, Durante M, Sgambellone S, Chini J, Baratta F, Aragno M, Mastrocola R, Masini E, **Collino M**. Reduced Susceptibility to Sugar-Induced Metabolic Derangements and Impairments of Myocardial Redox Signaling in Mice Chronically Fed with D-Tagatose when Compared to Fructose. *Oxid Med Cell Longev*. 2018 Sep 19;2018:5042428.
89. Al Zoubi S, Chen J, Murphy C, Martin L, Chiazza F, Collotta D, Yaqoob MM, **Collino M**, Thiemermann C. Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF- κ B. *Front Immunol*. 2018 Dec 18;9:2996. doi: 10.3389/fimmu.2018.02996. eCollection 2018.
90. Zuurbier CJ, Abbate A, Cabrera-Fuentes HA, Cohen MV, **Collino M**, De Kleijn DPV, Downey JM, Pagliaro P, Preissner KT, Takahashi M, Davidson SM. Innate immunity as a target for acute cardioprotection. *Cardiovasc Res*. 2019 Jun 1;115(7):1131-1142. doi: 10.1093/cvr/cvy304.
91. Băbțan AM, Ilea A, Boșca BA, Crișan M, Petrescu NB, **Collino M**, Sainz RM, Gerlach JQ, Câmpian RS. Advanced glycation end products as biomarkers in systemic diseases: premises and perspectives of salivary advanced glycation end products. *Biomark Med*. 2019 Apr 10. doi: 10.2217/bmm-2018-0448.
92. Purvis GSD*, **Collino M***, Loiola RA, Baragetti A, Chiazza F, Brovelli M, Sheikh MH, Collotta D, Cento A, Mastrocola R, Aragno M, Cutrin JC, Reutelingsperger C, Grigore L, Catapano AL, Yaqoob MM, Norata GD, Solito E, Thiemermann C. Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. *Front Immunol*. 2019 Mar 27;10:571. doi: 10.3389/fimmu.2019.00571. eCollection 2019. ***Collino and Purvis are co-first authors**
93. Polati E, Canonico PL, Schweiger V, **Collino M**. Tapentadol: an overview of the safety profile. *J Pain Res*. 2019 May 16; 12:1569-1576. doi: 10.2147/JPR.S190154. eCollection 2019. Review.
94. Romualdi P, Grilli M, Canonico PL, **Collino M**, Dickenson AH. Pharmacological rationale for tapentadol therapy: a review of new evidence. *J Pain Res*. 2019 May 16;12:1513-1520. doi: 10.2147/JPR.S190160. eCollection 2019.
95. O'Riordan CE, Purvis GSD, Collotta D, Chiazza F, Wissuwa B, Al Zoubi S, Stiehler L, Martin L, Coldewey SM, **Collino M**, Thiemermann C. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice. *Front Immunol*. 2019 Sep 6;10:2129. doi: 10.3389/fimmu.2019.02129. eCollection 2019.
96. Baratta F, Simiele M, Pignata I, Ravetto Enri L, Torta R, De Luca A, **Collino M**, D'Avolio A, Brusa P. Development of Standard Operating Protocols for the Optimization of Cannabis-Based

- Formulations for Medical Purposes. *Front Pharmacol.* 2019 Jun 25; 10:701. doi: 10.3389/fphar.2019.00701. eCollection 2019.
97. Felicetti F, Cento AS, Fornengo P, Cassader M, Mastrocola R, D'Ascenzo F, Settanni F, Benso A, Arvat E, **Collino M**, Fagioli F, Aragno M, Brignardello E. Advanced glycation end products and chronic inflammation in adult survivors of childhood leukemia treated with hematopoietic stem cell transplantation. *Pediatr Blood Cancer.* 2020; 67:e28106. doi: 10.1002/pbc.28106.
 98. Zechendorf E, O'Riordan CE, Stiehler L, Wischmeyer N, Chiazza F, Collotta D, Denecke B, Ernst S, Müller-Newen G, Coldewey SM, Wissuwa B, **Collino M**, Simon TP, Schuerholz T, Stoppe C, Marx G, Thiemermann C, Martin L. Ribonuclease 1 attenuates septic cardiomyopathy and cardiac apoptosis in a murine model of polymicrobial sepsis. *JCI Insight.* 2020 Apr 23;5(8). e131571. doi: 10.1172/jci.insight.131571.
 99. Cepas V, **Collino M**, Mayo JC, Sainz RM. Redox Signaling and Advanced Glycation Endproducts (AGEs) in Diet-Related Diseases. *Antioxidants (Basel).* 2020 Feb 6;9(2). pii: E142. doi: 10.3390/antiox9020142.
 100. Ferrigno A, Di Pasqua LG, Palladini G, Berardo C, Verta R, Richelmi P, Perlini S, Collotta D, **Collino M***, Vairetti M* Transient Expression of Reck Under Hepatic Ischemia/Reperfusion Conditions Is Associated With Mapk Signaling Pathways. *Biomolecules* 2020 May 11;10(5):E747. doi: 10.3390/biom10050747. * **Collino and Vairetti are co-last authors**
 101. Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C, Verta R, Alves GF, Gaudio G, Fava F, Yaqoob M, Aragno M, Tuohy K, Thiemermann C, **Collino M**. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. *Mol Metab.* 2020; 39:101009. doi: 10.1016/j.molmet.2020.101009.
 102. Purvis GSD, **Collino M**, Aranda-Tavio H, Chiazza F, O'Riordan CE, Zeboudj L, Mohammad S, Collotta D, Verta R, Guisot NES, Bunyard P, Yaqoob MM, Greaves DR, Thiemermann C Inhibition of Bruton's TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation. *Br J Pharmacol.* 2020;177(19): 4416-4432. doi: 10.1111/bph.15182.
 103. Bertocchi I, Foglietta F, Collotta D, Eva C, Brancaleone V, Thiemermann C, **Collino M**. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing. *Br J Pharmacol.* 2020; 177(21):4921-4930. 10.1111/bph.15229. doi: 10.1111/bph.15229.
 104. Mastrocola R, Collotta D, Gaudio G, Le Berre M, Cento AS, Ferreira Alves G, Chiazza F, Verta R, Bertocchi I, Manig F, Hellwig M, Fava F, Cifani C, Aragno M, Henle T, Joshi L, Tuohy K, **Collino M** Effects of Exogenous Dietary Advanced Glycation End Products on the Cross-Talk Mechanisms Linking Microbiota to Metabolic Inflammation. *Nutrients.* 2020 Aug 19;12(9):E2497. doi: 10.3390/nu12092497.
 105. Penna C, Aragno M, Cento AS, Femminò S, Russo I, Bello FD, Chiazza F, Collotta D, Alves GF, Bertinaria M, Zicola E, Mercurio V, Medana C, **Collino M***, Pagliaro P*. Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades. *Oxid Med Cell Longev.* 2020; 2020:9219825. doi: 10.1155/2020/9219825 * **Collino and Pagliaro are co-last authors**

106. Chen J., Purvis G, Collotta D, Al Zoubi S., Sugimoto MA, Cacace A, Martin L., Colas RA, **Collino M**, Dalli J, Thiernemann C. RvE1 Attenuates Polymicrobial Sepsis-Induced Cardiac Dysfunction and Enhances Bacterial Clearance. *Front Immunol.* 2020; 11:2080. doi: 10.3389/fimmu.2020.02080
107. O'Riordan C.E., Purvis G.S.D., Collotta D., Krieg N., Wissuwa B., Sheikh M.H., Alves G.F., Mohammad S., Callender L.A., Coldewey S.M., **Collino M.**, Greaves D.R., Thiernemann C.. X-Linked Immunodeficient Mice with No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure. *Front Immunol.* 2020; 11:581758. doi: 10.3389/fimmu.2020.581758. eCollection 2020.
108. Cialie` Rosso M, Stilo F, Squara S, Liberto E, Mai S, Mele C, Marzullo P, Aimaretti G, Reichenbach S.E., **Collino M.**, Bicchi C., Cordero C. "Exploring Extra-Dimensions to Capture Saliva Metabolite Fingerprints from Metabolically Healthy and Unhealthy Obese Patients by Comprehensive Two-Dimensional Gas Chromatography Featuring Tandem Ionization Mass Spectrometry" *Analytical and Bioanalytical Chemistry, Anal Bioanal Chem.* 2021;413(2):403-418. doi: 10.1007/s00216-020-03008-6.
109. Mhd Omar NA, Frank J, Kruger J, Dal Bello F, Medana C, **Collino M**, Zamaratskaia G, Michaelsson K, Wolk A, Landberg R. Effects of High Intakes of Fructose and Galactose, with or without Added Fructooligosaccharides, on Metabolic Factors, Inflammation, and Gut Integrity in a Rat Model. *Mol. Nutr. Food Res.* 2021, 65, 2001133 doi: 10.1002/mnfr.202001133.
110. Baratta F, Simiele M, Pignata I, Ravetto Enri L, D'Avolio A, Torta R, De Luca A, **Collino M**, Brusa P. *Cannabis*-Based Oral Formulations for Medical Purposes: Preparation, Quality and Stability. *Pharmaceuticals (Basel).* 2021; 14(2):171. doi: 10.3390/ph14020171.
111. Di Pasqua LG, Berardo C, Cagna M, Verta R, Collotta D, Nicoletti F, Ferrigno A, **Collino M***, Vairetti M. Metabotropic Glutamate Receptor Blockade Reduces Preservation Damage in Livers from Donors after Cardiac Death. *Int J Mol Sci.* 2021; 22(5):2234. doi: 10.3390/ijms22052234 * **Collino and Vairetti are co-last authors**
112. Sordi R, Chiazza F, Collotta D, Migliaretti G, Colas RA, Vulliamy P, Brohi K, Dalli J, **Collino M**, Thiernemann C. Resolvin D1 Attenuates the Organ Injury Associated With Experimental Hemorrhagic Shock. *Ann Surg.* 2021;273(5):1012-1021 doi: 10.1097/SLA.0000000000003407
113. Durante M, Sgambellone S, Lucarini L, Failli P, Laurino A, Collotta D, Provensi G, Masini E, **Collino M**. D-Tagatose Feeding Reduces the Risk of Sugar-Induced Exacerbation of Myocardial I/R Injury When Compared to Its Isomer Fructose. *Front Mol Biosci.* 2021; 8:650962. doi: 10.3389/fmolb.2021.650962. eCollection 2021.
114. Mastrocola R, Bello FD, Cento AS, Gaens K, Collotta D, Aragno M, Medana C, **Collino M**, Wouters K, Schalkwijk CG. Altered hepatic sphingolipid metabolism in insulin resistant mice: role of advanced glycation endproducts. *Free Radic Biol Med.* 2021, 169:425-435 doi: 10.1016/j.freeradbiomed.2021.04.028.
115. Wouters K, Cento AS, Gaens KH, Teunissen M, Scheijen JLJM, Barutta F, Chiazza F, Collotta D, Aragno M, Gruden G, **Collino M**, Schalkwijk CG, Mastrocola R. Deletion of RAGE fails

- to prevent hepatosteatosis in obese mice due to impairment of other AGEs receptors and detoxifying systems. *Sci Rep.* 2021;11(1):17373. doi: 10.1038/s41598-021-96859-7
116. Cepas V, Manig F, Mayo JC, Hellwig M, Collotta D, Sanmartino V, Carrocera-Pumarino R, **Collino M**, Henle T, Sainz RM. In Vitro Evaluation of the Toxicological Profile and Oxidative Stress of Relevant Diet-Related Advanced Glycation End Products and Related 1,2-Dicarbonyls. *Oxid Med Cell Longev.* 2021;2021:9912240. doi: 10.1155/2021/9912240.
 117. Mohammad S, Al Zoubi S, Collotta D, Krieg N, Wissuwa B, Ferreira Alves G, Purvis GSD, Norata GD, Baragetti A, Catapano AL, Solito E, Zechendorf E, Schürholz T, Correa-Vargas W, Brandenburg K, Coldewey SM, **Collino M**, Yaqoob MM, Martin L, Thiemermann C. A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. *Front Immunol.* 2021; 12:701275. doi: 10.3389/fimmu.2021.701275.
 118. Rubin E, Pippione AC, Boyko M, Einaudi G, Sainas S, Collino M, Cifani C, Lolli ML, Abu-Freha N, Kaplanski J, Boschi D, Azab AN. A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats. *Brain Sci.* 2021 Dec 28;12(1):35. doi: 10.3390/brainsci12010035
 119. Felicetti F, Aimaretti E, Dal Bello F, Gatti F, Godono A, Saba F, Einaudi G, **Collino M**, Fagioli F, Aragno M, Brignardello E. Advanced glycation end products and their related signaling cascades in adult survivors of childhood Hodgkin lymphoma: A possible role in the onset of late complications. *Free Radic Biol Med.* 2021;178:76-82. doi: 10.1016/j.freeradbiomed.2021.11.036
 120. Patel NK, Oliveira F, Ramos HP, Aimaretti E, Alves GF, Coldewey SM, **Collino M**, Sordi R, Thiemermann C. Inhibition of Bruton's tyrosine kinase activity attenuates trauma-induced multiple organ dysfunction in rats. *Ann Surg.* 2022, accepted for publication
 121. Gallone G, Baldetti L, Angelini F, Saglietto A, Bellettini M, Beneduce A, Ranotti V, Chiarito M, Leone PP, Pagnesi M, De Filippo O, Landra F, Bruno F, Marengo G, **Collino M**, Ferrante G, Stefanini GG, Colombo A, Al-Lamee R, Francis DP, Jolicoeur ME, Henry TD, Giannini F, D'Ascenzo F, De Ferrari GM. Impact of the placebo effect on symptoms quality of life and functional outcomes in angina pectoris: A meta-analysis of randomized placebo-controlled trials. *Can J Cardiol.* 2022;38(1):113-122. doi: 10.1016/j.cjca.2021.04.022
 122. Alves GF, Aimaretti E, Einaudi G, Mastrocola R, de Oliveira JG, Collotta D, Porchietto E, Aragno M, Cifani C, Sordi R, Thiemermann C, Fernandes D, **Collino M**. Pharmacological Inhibition of FAK-Pyk2 Pathway Protects Against Organ Damage and Prolongs the Survival of Septic Mice. *Front Immunol.* 2022;13:837180. doi: 10.3389/fimmu.2022.837180.

LIBRI

1. **Collino M**, Giorgis M, Marini E., Miro A, Quaglia F, Ungaro F. "L'esame di Stato per Farmacisti". Ed. EdiSES 2018 (ISBN: 9788833190167)

CAPITOLI DI LIBRI

1. Fantozzi R., **Collino M.** "Immuotossicologia" pag. 153-162, in P. Ghi, Allegrucci M., Di Paolo A., Fantozzi R., Govoni S., Maffei F. "Tossicologia" Ed. Minerva Medica, Torino 2009
2. Benetti E., Patel N., **Collino M.** "PPAR Agonism as new pharmacological approach to the management of acute ischemic stroke" pag. 511-529 in "Advances in the preclinical study of ischemic stroke" Ed. InTech, Rijeka, Croatia, March 2012
3. Chiazza F, **Collino M.** "Peroxisome proliferator activated receptors in glucose control", chapter 9, pg.105-114, in "Molecular Nutrition and Diabetes" Ed. Academic Press, Elsevier (Print Book ISBN :9780128015858), 2016
4. Ferrigno A, Di Pasqua LG, Palladini G, Berardo C, Verta R, Richelmi P, Perlini S, Collotta D, **Collino M.**, Vairetti M "Transient Expression of Reck Under Hepatic Ischemia/Reperfusion Conditions Is Associated With Mapk Signaling Pathways" in Matrix Metalloproteinases in Health and Disease. Ed MDPI, Basel, Switzerland (ISBN 978-3-03943-052-9 (Hbk); ISBN 978-3-03943-053-6 (PDF) <https://doi.org/10.3390/books978-3-03943-053-6>), September 2020

Proceedings su RIVISTA

1. **Collino M.**, Dianzani C., Lombardi G., Cassone M.C., Fantozzi R. Priming effects of substance P on calcium changes induced by interleukin-8 in human neutrophils. Pharmacological Research, 43(Suppl A): 28, 2001
2. Dianzani C., **Collino M.**, Fantozzi R. Substance P evokes neutrophil adhesion to endothelial cells. Pharmacological Research, 43(Suppl A): 29, 2001
3. Patel NSA, **Collino M.**, Collin M, Thiemermann C The selective PPAR gamma antagonist GW9662 abolished the protection afforded by Ips pretreatment in a rat model of renal ischemia/reperfusion injury SHOCK, 23 (Suppl.3):30-31, 2005
4. Fantozzi R. and **Collino M.** NSAIDs IN CANCER PAIN- 12th International Pain Clinic World Society of Pain Clinicians – Turin (Italy), July 4-7, 2006. Volume ISBN 88-7587-262-7, pag.163-165
5. **Collino M.** and Fantozzi R.. DRUG THERAPY OF HEADACHE - 12th International Pain Clinic World Society of Pain Clinicians – Turin (Italy), July 4-7, 2006. Volume ISBN 88-7587-262-7, pag.163-165
6. Sivarajah A, **Collino M.**, Yasin M, Cuzzocrea S, and Thiemermann C "Hydrogen sulfide in disease" Inflammation Research Vol.56, Supplement 2, Pages: S261-261, 2007
7. Yasin M., Shintani Y, **Collino M.**, Takahashi K, Salem H, Kapoor A, Rucklidge G, Suzuki K, Thiemermann C, Bone Marrow Mononuclear Cell Therapy upon Reperfusion Reduces Myocardial Infarct Size by Activating the PI3K/Akt Survival Pathway. Circulation Vol.118, Issue 18, Supplement 2, Pages: S380-S380-23, 2008
8. Tripatara P, Patel N, **Collino M.**, Gallicchio M, Kieswich J, Castiglia S, Benetti E, Stewart K, Brown P, Yaqoob M, Fantozzi R, Thiemermann C "Generation of endogenous hydrogen sulphide by

- cystathionine gamma-lyase limits renal ischaemia/reperfusion injury and dysfunction” . Proceedings of the British Pharmacological Society. pA2 Vol. 6, Issue 2, Page:003P, 2008
9. **Collino M**, Castiglia S, Benetti E, Miglio G, Thiemermann C, Fantozzi R. PPAR- β/δ activation protects against renal ischemia/reperfusion injury in diabetic rats. Shock Vol.32, Supplement 1, Pages: 4-4, 2009
 10. Kapoor A., Shintani Y., **Collino M**, Bailey LK., Patel NSA, Sepodes B., Tripatara B., Castiglia S, Fantozzi R., Mota-Filipe H., Sukuki K., Mitchell JA., Thiemermann C, PPAR- β/δ activation attenuates organ injury/dysfunction and inflammation caused by endotoxin. Shock Vol.32, Supplement 1, Pages: 7-7, 2009
 11. Kapoor A., **Collino M**, Castiglia S, Fantozzi R., Thiemermann C, Activation of PPAR-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat. Shock Vol.32, Supplement 1, Pages: 23-23, 2009
 12. Nandra K., Takahashi K., **Collino M.**, Salem H., Patel N., Thiemermann C. “Acute-treatment with bone-marrow derived mononuclear cells attenuates the organ injury and dysfunction induced by haemorrhagic shock” Proceedings of the British Pharmacological Society. pA2 Vol. 7, Issue 4, Page:136P, 2009
 13. Kapoor A., Shintani Y., **Collino M.**, Bailey L., Patel N., Sepodes B., Tripatara P., Castiglia S., Fantozzi R., Mota-Filipe H., Suzuki K., Mitchell J., Thiemermann C. “Protective role of PPAR- β/δ in cardiac dysfunction and organ injury/inflammation caused by endotoxin in mice” Proceedings of the British Pharmacological Society. pA2 Vol. 7, Issue 4, Page:041C, 2009
 14. Kapoor A, Shintani Y, **Collino M**, L K Bailey, N S A Patel, B Sepodes, P Tripatara, Castiglia S, Fantozzi R, H Mota-Filipe, K Suzuki, J A Mitchell, Thiemermann C. “Protective role of peroxisome proliferator-activated receptor beta/delta in cardiac dysfunction and organ injury/inflammation caused by endotoxin in mice”. Heart Vol.96 Issue: 4 :e8, 2010
 15. Kapoor A, Shintani Y, **Collino M**, Bailey L, Patel N, Sepodes B. “Protective role of PPAR-beta/delta in cardiac dysfunction and organ injury/inflammation caused by endotoxemia in mice”. Inflammation research Vol.59, Suppl. 1, Page: S20, 2010
 16. **Collino M**, Pini A., Mastroianni R., Benetti E., Bani D., Manoni M., Masini E., Fantozzi R. “Protective effects of a non-anticoagulant heparin-like polysaccharide derivative on cerebral and myocardial ischemia/reperfusion injury”. Shock Vol.36, Supplement 1, Pages: 11-11, 2011
 17. Kapoor A, Shintani Y, **Collino M**, Osuchowski M., Busch D., Patel NSA, Sepodes B, Castiglia S., Fantozzi R., Bailey L, Mota-Felipe H., Yaqoob MM., Suzuki K., Baharami S., Desvergne B., Mitchell JA., Thiemermann C. “Beneficial role of PPAR-beta/delta in septic shock”. Shock Vol.36, Supplement 1, Pages: 20-20, 2011
 18. Nandra K., Takahashi K., **Collino M.**, Benetti E., Wong WSF, Goh FY, Salem H., Suzuki K., Patel N., Thiemermann C. “Bone-marrow derived mononuclear cells protects against multiple organ ifailure in haemorrhagic shock through an Akt-dependent pathway induced by haemorrhagic shock” Shock Vol.36, Supplement 1, Pages: 26-26, 2011

19. Coldewey S.M., Khan A., Rogazzo M., **Collino M.**, Patel N.S.A, Kapoor A., Thiernemann C. Erythropoietin reduces the acute kidney injury in experimental sepsis via activation of the beta-common receptor. *Shock* Vol.37, Supplement 1, Pages: 52-52, 2012
20. Khan A., Coldewey S.M., Kapoor A., Patel N.S.A, Thiernemann C. Rogazzo M., **Collino M.** Erythropoietin attenuates cardiac injury in experimental sepsis via activation of the beta-common receptor. *Shock* Vol.37, Supplement 1, Pages: 55-56, 2012
21. Nandra KK, Patel NS; Harwood S.; **Collino M.**; Rogazzo, M.; Yaqoob, M.; Thiernemann C. Three day pre-treatment with erythropoietin attenuates the organ injury and dysfunction induced by hemorrhagic shock in the rat by a mechanism independent of endothelial progenitor cell mobilization. . *Shock* Vol.37, Supplement 1, Pages: 96-97, 2012
22. Rosa AC, Grange C, Pini A, Katebe MA, Benetti E, **Collino M**, Miglio G, Bani D, Camussi G, Chazot PL, Fantozzi R. Histamine H4 receptors are present in the kidney of diabetic rats. *Diabetologia* 55:S459, 2012
23. Benetti E, **Collino M**, Rogazzo M., Aragno M., Mastrocola R., Fantozzi R. High-fructose corn syrup (HFCS) diet induce an NLRP-3 inflammasome-mediated response in the kidney: protection by PPARbeta/delta agonist. *Diabetologia*, Vol. 55, Suppl. 1: S271, 2012
24. **Collino M**, Rogazzo M, Pini A, Benetti E, Rosa AC, Fantozzi R, Bani D, Masini E. Acute treatment with relaxin attenuates the injury/ dysfunction induced by renal ischemia/reperfusion injury. *Italian Journal of Anatomy and Embryology*, Vol . 118, n . 1 (Suppl .): 74-76, Jan. 2014. ISSN 2038-5129
25. Mastrocola R, Nigro D, Chiazza F, **Collino M**, Aragno M. Fructose-Derived Advanced Glycation End-Products Evoke Skeletal Muscle Damage in Mice by Multiple Interference with SCAP-SREBP Pathway. *Free Radical Biology and Medicine* 76, Supplement 1, November 2014, Pages S101.
26. Paternostro c.; E. Benetti; S. Cannito; E. Novo; F. Chiazza; M. Rogazzo; C. Bocca; R. Fantozzi; D. Povero; A. Feldstein; **M. Collino**; M. Parola. P265 Microparticles released as a consequence of lipid-induced toxicity promote NLRP3 inflammasome activation in HepG2 cells. *Journal of Hepatology* 2014 vol. 60: S153
27. Chen J, Chiazza F, **Collino M**; Patel NSA, Coldewey SM, Patel NS, Thiernemann C. Gender dimorphism of the cardiac dysfunction in murine sepsis: Signalling mechanisms and age-dependency. *Shock*, vol. 41 (S2), page 35, 2014
28. R Sordi, F Chiazza, N Patel, **M Collino**, C Thiernemann. A Selective I κ B Kinase Inhibitor (IKK16) Attenuates The Organ Injury / Dysfunction Associated with Haemorrhagic Shock In The Rat. *Proceedings of the British Pharmacological Society*. pA2 Vol. 12, Issue 3, Page:083P, 2014
29. J Chen, J Kieswich, F Chiazza, N Patel, **M Collino**, M Yaqoob, C Thiernemann. Pre-existing chronic kidney disease worsens the myocardial dysfunction caused by sepsis in mice. *Proceedings of the British Pharmacological Society*. pA2 Vol. 12, Issue 3, Page:055P, 2014

30. J Chen, J Kieswich, F Chiazza, Gobetti T, N Patel, Perretti M, **M Collino**, M Yaqoob, C Thiernemann. The cardiac dysfunction caused by sepsis in animals with chronic kidney disease is attenuated by inhibiting I kappa B kinase. *Shock*, vol 43, issue 6 (S1):92-93, P144
31. R Sordi, K Nandra, F Chiazza, N Patel, **M Collino**, Brohi K, C Thiernemann. Artesunate protects against the organ injury and dysfunction induced by severe hemorrhage and resuscitation. *Shock*, vol 43, issue 6 (S1):76-77, P106
32. F Johnson, N Patel, **M Collino**, E Bennetti, C Thiernemann. The late inhibition of inhibitor of I κ B kinase attenuates acute kidney injury and the subsequent development of fibrosis in a rat model of ischemia/reperfusion injury. *Shock*, vol 44 (S2):10 2015
33. J Chen, J Kieswich, F Chiazza, Gobetti T, N Patel, Perretti M, **M Collino**, M Yaqoob, C Thiernemann. The cardiac dysfunction caused by sepsis in animals with chronic kidney disease is attenuated by inhibiting I kappa B kinase. *Shock*, vol 44 (S2):16, 2015
34. R Sordi, KK Nandra, F Chiazza, NSA Patel, K Brohi, **M Collino**, C Thiernemann. Trauma organ protection with artesunate: preclinical efficacy of an antimalarial drug with excellent safety profile and planned phase II RCT. *Shock*, vol 44 (S2):1, 2015
35. Masini E, Nistri S, Vannacci A, Pini A, **Collino M**, Bani D. Histamine and relaxin: an intriguing connection. *Inflammation Research*, vol 64: S47-S47, 2015, 2015
36. **Collino M**. Cardiometabolic diseases and the inflammasome: a key and innovative pharmacological target? *J Diabetes Metab* 2015, 6:10 (ISSN 2155-6156 JMD)
37. Mastrocola R, **Collino M**, Nigro D, Medana C, Dal Bello F, Chiazza F, Boccuzzi G, Aragno M. Fructose-derived advanced glycation end-products induce a negative crosstalk between lipogenesis and muscle reprogramming in mice through SREBP-1c. *Diabetologia* 2015, Vol 58: S559-S560
38. E. Benetti, G. Vitarelli, **M. Collino**, R. Mastrocola, J.C. Cutrin, F. Chiazza, D. Nigro, R. Fantozzi. Effects of empagliflozin in a murine model of diet-induced insulin resistance: A role for NLRP3 inflammasome inhibition? *Diabetologia* 2015, Vol 58: S327-S328
39. SM Coldewey, E Benetti, **M Collino**, M Bauer, A Huwiler, C Thiernemann. Enhanced sphingosine-1-phosphate levels ameliorate murine septic cardiomyopathy. *Intensive Care Medicine Experimental*, vol 3 (S1): A615
40. Femminò , F. Chiazza, R. Mastrocola, F. Tullio, C. Penna, D. Nigro, G. Alloatti, M. Cocco, D. Garella, M. Bertinaria, R. Fantozzi, M. Aragno, **M. Collino**, P. Pagliaro. Is NLRP3 inflammasome a new pharmacological target in myocardial ischemia/reperfusion injury? *VASCULAR PHARMACOLOGY* Volume: 75 Pages: 51-51, 2015
41. F. Tullio, F. Chiazza, R. Mastrocola , C. Penna, D. Nigro, V. Fracasso, G. Alloatti, R. Fantozzi, M. Aragno, **M. Collino**, P. Pagliaro Exacerbation of myocardial ischemia/reperfusion injury induced by high-fat-high-fructose (HFHF) diet: Role of NLRP3 inflammasome *VASCULAR PHARMACOLOGY* Volume: 75 Pages: 65-66, 2015

42. Chen J, Kieswich JE, Chiazza F, Moyes AJ, Gobbetti T, Purvis GS, Salvatori DC, Patel NS, Perretti M, Hobbs AJ, **Collino M**, Yaqoob MM, Thiernemann C. I κ B Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in mice with CKD. *Shock*, vol 46 (4, Suppl 2) 29-30, 2016
43. Thiernemann C., Sordi R, Nandra KK, Chiazza F, Johnson FL, Cabrera CP, Torrance HD, Yamada N, Patel NS, Barnes MR, Brohi K, **Collino M**. Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation. *Shock*, vol 46 (4, Suppl 2) 16-7, 2016
44. Spallotta F, Cencioni C, Atlante S, Garella D, Cocco M, Mori M, Mastrocola R, Kuenne C, Guenther S, Nanni S, Azzimato V, Zukunft S, Kornberger A, Sürün D, Schnütgen F, von Melchner H, Di Stilo A, Aragno M, Braspenning M, van Criekinge W, De Blasio MJ, Ritchie RH, Zaccagnini G, Martelli F, Farsetti A, Fleming I, Braun T, Beiras-Fernandez A, Botta B, **Collino M**, Bertinaria M, Zeiher AM, Gaetano C. Cardiac Epi-Metabolic Signature Revealed by Integrated Omics Approach in Diabetic Patients: Rescue by Active DNA Demethylation via TET-TDG Complex Reactivation Conference: Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium Location: New Orleans, LA Date: NOV 12-16, 2016 Sponsor(s): Amer Heart Assoc. *CIRCULATION* Volume: 134 Supplement: 1 Meeting Abstract: 19033 Published: NOV 11 2016
45. Collino, M.; Chiazza, F.; Collotta, D.; **Collino, M**, Cento, AS; Nigro, D ; Bitonto, V; Cutrin, JC; Aragno, M; Mastrocola, R. The AGEs inhibitor pyridoxamine prevents kidney injury and dysfunction in mice fed high-fat high-fructose diet Conference: 53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Lisbon, PORTUGAL Date: SEP 11-15, 2017 Sponsor(s): European Assoc Study Diabet *DIABETOLOGIA* Volume: 60 Supplement: 1 Pages: S504-S505 Meeting Abstract: 1096 Published: SEP 2017
46. Mastrocola, R.; Cento, A. S.; Chiazza, F.; Ferrocino, I ; Bitonto, V; Nigro, D; Querio, G; Rantsiou, K; Cutrin, JC ; Aragno, M; Liberto, E ; Masini, E; Cordero, C ; Cocolin, L ; **Collino, M**. Toxicological impact of high fructose intake on gut microbiota and liver/intestine integrity: Any differences between solid and liquid formulations? Conference: 53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Lisbon, PORTUGAL Date: SEP 11-15, 2017 Sponsor(s): European Assoc Study Diabet Volume: 60 Supplement: 1 Pages: S245-S245 Meeting Abstract: 538 Published: SEP 2017
47. Yamada, Noriaki; Martin, Lukas; Zechendorf, Elisabeth; Chiazza, F ; Varrone, B ; **Collino, M** ; Shepherd, J ; Heinbockel, L ; Correa, W; Brandenburg, K ; Marx, G ; Schuerholz, T ; Brohi, K ; Thiernemann, C. A NOVEL SYNTHETIC, HOST-DEFENCE PEPTIDE PROTECTS AGAINST ORGAN INJURY/DYSFUNCTION IN A RAT-MODEL OF SEVERE HEMORRHAGIC SHOCK Conference: 40th Annual Conference on Shock Location: Fort Lauderdale, FL Date: JUN 03-06, 2017 *SHOCK* Volume: 47 Issue: 6 Supplement: 1 Pages: 116-117 Meeting Abstract: P204 Published: JUN 2017
48. Martin, Lukas; Chen, Jianmin; Zechendorf, Elisabeth; Chiazza, F ; Oggero, S ; **Collino, M** ; Marx, G ; Schuerholz, T ; Thiernemann, C ROLE OF THE beta-D-ENDOGLUCURONIDASE HEPARANASE IN SEPTIC CARDIOMYOPATHY Conference: 40th Annual Conference on Shock Location: Fort Lauderdale, FL Date: JUN 03-06, 2017 *SHOCK* Volume: 47 Issue: 6 Supplement: 1 Pages: 129-129 Meeting Abstract: P233 Published: JUN 2017

49. Purvis, GSD ; Chiazza, F ; **Collino, M** ; Solito, E ; Thiemermann, C Endogenous Annexin-A1 is a Protective Determinant in HFD-induced Insulin Resistance and Diabetic Nephropathy Conference: Annual Meeting of the American-Society-for-Pharmacology-and-Experimental-Therapeutics (ASPET) at Experimental Biology Meeting Location: Chicago, IL Date: APR 22-26, 2017 Sponsor(s): Amer Soc Pharmacol & Expt Therapeut; Amer Assoc Anatomists; Amer Physiol Soc; Amer Soc Biochem & Mol Biol; Amer Soc Investigat Pathol; Amer Soc Nutr. FASEB JOURNAL Volume: 31 Supplement: 1 Meeting Abstract: 853.3 Published: APR 2017
50. Purvis, GSD ; Chiazza, F ; Solito, E ; **Collino, M** ; Thiemermann, C Endogenous annexin-A1 is a protective determinant in high-fat diet (HFD)-induced insulin resistance and diabetic nephropathy DIABETIC MEDICINE Volume: 34 Special Issue: SI Supplement: 1 Pages: 26-26 Meeting Abstract: A59 Published: MAR 2017 DOI: 10.1111/dme.42_13304
51. Cento Alessia S.; Chiazza F; Collotta D; Barutta F; Aragno M; Scheijen J; **Collino M**, Gaens KH; Schalkwijk CG; Wouters K; Mastrocola R. Genetic deletion of RAGE in Dbdb mice interferes with AGEs receptors and detoxifying systems in liver. Conference: 19th Biennial Meeting of the Society-for-Free-Radical-Research-International (SFRRRI) Location: Lisbon, PORTUGAL Date: 2018 FREE RADICAL BIOLOGY AND MEDICINE Volume: 120 Supplement: 1 Pages: S97-S97 Meeting Abstract: P-174 Published: MAY 20 2018
52. Cento Alessia S.; Felicetti F; Mastrocola R; Collotta D; **Collino M**; Aragno M; Brignardello E. Redox unbalance and inflammation in long-term survivors of childhood acute lymphoblastic leukemia Conference: 19th Biennial Meeting of the Society-for-Free-Radical-Research-International (SFRRRI) Location: Lisbon, PORTUGAL Date: 2018. FREE RADICAL BIOLOGY AND MEDICINE Volume: 120 Pages: S105-S105 Supplement:1 Meeting Abstract: P-200 DOI:10.1016/j.freeradbiomed.2018.04.347
53. Cento Alessia S.; Gaens KH; Collotta D; Chiazza F; Barutta F; Scheijen J; Aragno M; **Collino M**, Wouters K; Schalkwijk CG; Mastrocola R. AGEs induce alterations of sphingolipids metabolism in the liver of genetically- and diet-induced diabetic mice. Conference: 54th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Berlin, GERMANY Date: OCT 01-05, 2018. DIABETOLOGIA Volume: 61; Pages: S268-S268; Supplement: 1; Meeting Abstract: 553 Published: OCT 2018
54. Mastrocola R., Cento Alessia S.; Collotta D; Chiazza F; Barutta F; Scheijen J; Aragno M; Gaens KH; **Collino M**, Schalkwijk CG; Wouters K; Genetic deletion of RAGE in db/db mice interferes in the liver with other AGE-receptors and AGE-detoxifying systems sustaining lipogenesis and inflammation. Conference: 54th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Berlin, GERMANY Date: OCT 01-05, 2018. DIABETOLOGIA Volume: 61 Pages: S258-S258, Supplement: 1, Meeting Abstract: 528, Published: OCT 2018
55. Cento, A. S.; Collotta, D.; Chiazza, F.; Aragno, M; **Collino, M**; Mastrocola, R. Inhibition of AGEs by pyridoxamine prevents diet-induced systemic inflammation and skeletal muscle insulin resistance by restoring SphK/S1P3/RhoA signalling. Conference: 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Barcelona, SPAIN Date: SEP 16-20, 2019. DIABETOLOGIA Volume: 62 Special Issue: SI Supplement: 1 Pages: S317-S318 Meeting Abstract: 662 Published: SEP 2019

56. Penna, C; Femmino, S; Chiazza, F; Collotta, D; Aragno, M; Bertinaria, M; **Collino, M**; Pagliaro, P. Ischemia AND reperfusion injury: modulation of damage with ticagrelor AND specific NLRP3 inflammatory inhibitor. Conference: 80th SIC National Congress Location: Rome, ITALY Date: DEC 12-15, 2019. EUROPEAN HEART JOURNAL SUPPLEMENTS Volume: 21 Issue: J Pages: J117-J118 Meeting Abstract: 546 Published: DEC 201
57. Berardo, C; Verta, R; Di Pasqua, LG; Collotta, D; Siciliano, V; Nicoletti, F; Vairetti, M; **Collino, M**; Ferrigno, A Cold ischemic injury is reduced by the mGluR5 negative allosteric modulator MPEP in rat livers from cardiac death donors DIGESTIVE AND LIVER DISEASE, Volume: 52, Pages: E66-E66, Supplement: 1, Meeting Abstract: F-42, DOI: 10.1016/j.dld.2019.12.083, Published: FEB 2020
58. Gaudio G, Collotta D, Chiazza F, Mastrocola R, Cento AS, Fava F, Aragno M, **Collino M** Tuohy K, Effects of Exogenous Dietary Advanced Glycation End Products on the Cross-Talk Mechanisms Linking Microbiota to Metabolic Inflammation. PROCEEDINGS OF THE NUTRITION SOCIETY Volume: 79 Issue: OCE2 Pages: E368-E368 Published: 2020
59. Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C, Verta R, Alves GF, Gaudio G, Fava F, Yaqoob M, Aragno M, Tuohy K, Thiernemann C, **Collino M**. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. DIABETOLOGIA Volume: 63 Issue: SUPPL 1 Special Issue: SI Supplement: 1 Pages: S241-S242 Meeting Abstract: 500 Published: SEP 2020
60. Mastrocola R, Collotta D, Gaudio G, Le Berre M, Cento AS, Ferreira Alves G, Chiazza F, Verta R, Bertocchi I, Manig F, Hellwig M, Fava F, Cifani C, Aragno M, Henle T, Joshi L, Tuohy K, **Collino M** Effects of Exogenous Dietary Advanced Glycation End Products on the Cross-Talk Mechanisms Linking Microbiota to Metabolic Inflammation. DIABETOLOGIA Volume: 63 Issue: SUPPL 1 Special Issue: SI Supplement: 1 Pages: S431-S432 Meeting Abstract: 902 Published: SEP 2020
61. Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C, Verta R, Alves GF, Gaudio G, Fava F, Yaqoob M, Aragno M, Tuohy K, Thiernemann C, **Collino M**. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. Pharmadvances. Volume 3, issue 1, 2021 Meeting Abstract page 104, doi:10.36118/pharmadvances.03.2021.01
62. Collotta D, Purvis GSD, Aranda-Tavio H, Chiazza F, O'Riordan CE, Zeboudj L, Mohammad S, Verta R, Guisot NES, Bunyard P, Yaqoob MM, Greaves DR, Thiernemann C, **Collino M**. Inhibition of Bruton's TK regulates macrophage NF- κ B and NLRP3 inflammasome activation in metabolic inflammation. Pharmadvances. Volume 3, issue 1, 2021 Meeting Abstract page 105, doi:10.36118/pharmadvances.03.2021.01
63. **Collino M**. Pharmacological Targeting of key proximal drivers of metaflammation in diet-induced metabolic diseases. Pharmadvances. Volume 3, issue 1, 2021 Meeting Abstract page 322, doi:10.36118/pharmadvances.03.2021.01
64. E. Aimaretti, F. Felicetti, F. Dal Bello, F. Gatti, M. Cassader, C. Cifani, F. Fagioli, M. Aragno, **M. Collino**, E. Brignardello. The systemic inflammatory response in hodkigkin lymphoma survivors

- are advanced glycation end products potential players. *Pharmadvances*. Volume 3, special issue 2021 Meeting Abstract page 7, doi: 10.36118/pharmadvances.2021.17
65. D. Collotta, W. Hull, R., Mastrocola, E. Aimaretti, F. Chiazza, S. Cento, C. Murphy, R. Verta, G. Ferreira Alves, G. Gaudio, F. Fava, M. Aragno, K. Tuohy, C. Thiernemann, **M. Collino**. Potential repositioning of baricitinib for preventing diet-induced metabolic abnormalities: an in-vivo study. *Pharmadvances*. Volume 3, special issue 2021 Meeting Abstract page 12, doi: 10.36118/pharmadvances.2021.17
66. G. Einaudi, G. Ferreira Alves, D. Collotta, R. Mastrocola, F. Penna, C. Fornelli, E. Aimaretti, M. Aragno, M. Bertinaria, C. Cifani, **M. Collino**. Pharmacological targeting of cyclooxygenase to counteract metaflammation in an in-vivo model of diet-induced metabolic derangements. *Pharmadvances*. Volume 3, special issue 2021 Meeting Abstract page 16, doi: 10.36118/pharmadvances.2021.17
67. G. Ferreira Alves, E. Aimaretti, G. Einaudi, R. Mastrocola, J. Garcia Oliveira, D. Collotta, M. Aragno, C. Thiernemann, D. Fernandes, **M. Collino**. Inhibition of FAK-PYK2 pathway protects against organ damage and prolongs the survival of septic mice. *Pharmadvances*. Volume 3, special issue 2021 Meeting Abstract page 18, doi: 10.36118/pharmadvances.2021.17

Articoli e interviste su RIVISTE NAZIONALI

- 1 Beatrice M.A. Parola, Sara Alemanno, Martina Capilli, Irene Colasanto, Denise Fiorentino, Maddalena Marcato, Laura Pestrin, Stefania Strobino, Alessandra Varese, Elena Viglione, Guendalina Brunitto, Massimo Collino, Roberta Fruttero. Analisi descrittiva della spesa e del consumo del rituximab originator versus biosimilare in Regione Piemonte. *Bollettino Sifo* Vol. 67 n. 1-2:3-7, 2021
- 2 Collino M. Micosi cutanee: appropriatezza terapeutica e antimicotico-resistenza. *On Medicine*. Anno X; N 2 - luglio 2016
- 3 Massimo Collino "Appropriatezza terapeutica e antimicotico-resistenza: strategie di scelta", In *Medicine Review*, Suppl. al volume IX, N.9, dicembre 2015, ISSN: 2239-6470
- 4 Massimo Collino "La sfida degli ex Osp2", *Punto Effe*, anno XV, N. 17, pagg. 33-37, novembre 2014
- 5 Intervista per Il Venerdì di Repubblica, supplemento settimanale de la Repubblica, "UN'AMARA VERITÀ SULLO ZUCCHERO: CREA DIPENDENZA PERCHÉ AGISCE COME LA DROGA", 2 dicembre 2011, pagg. 86-89
- 6 Collino M. High dietary fructose intake: Sweet or bitter life? *World J Diabetes*. 2011; 2:77-81.

- 7 Massimo Collino "Prodotti di origine vegetale e sorveglianza delle reazioni avverse", Unifarma Notizie, anno XVII, N.1-2008, pagg. 28-33

PARTECIPAZIONE A CONGRESSI

1. **Collino M.**, Dianzani C., Lombardi G., Cassone M.C., Fantozzi R. Priming effects of substance P on calcium changes induced by interleukin-8 in human neutrophils. XXX National Congress of the Italian Pharmacological Society, Genova (Italy), 30 May -2th June, 2001
2. Dianzani C., **Collino M.**, Fantozzi R. Substance P evokes neutrophil adhesion to endothelial cells. XXX National Congress of the Italian Pharmacological Society, Genova (Italy), 30 May -2th June, 2001
3. **Collino M.**, Gallicchio M., Dianzani C., Fantozzi R. The adhesion of neutrophils to endothelial cells evoked by Substance P: effects of COX-2 inhibitors. XXXI National Congress of the Italian Pharmacological Society, Trieste (Italy), 26-29th June, 2003
4. Dianzani C., **Collino M.**, Fantozzi R. Tachykinin receptors detected on human endothelial cells. XXXI National Congress of the Italian Pharmacological Society, Trieste (Italy), 26-29th June, 2003
5. N. Patel, **M. Collino**, M. Collin and C. Thiemermann. The selective PPAR γ antagonist GW9662 abolished the protection afforded by LPS-pretreatment in a rat model of renal ischemia-reperfusion injury. XX National Congress of the American Society of Nephrology San Francisco (California) August 27 – September 2, 2005
6. **Collino M.**, N. S. A. Patel, M. Collin, C. Thiemermann and R. Fantozzi The selective PPAR γ antagonist GW9662 abolished the protection afforded by LPS-pretreatment in a rat model of renal ischemia/reperfusion injury. XXXII National Congress of the Italian Pharmacological Society, Naples (Italy), 1-4th June, 2005
7. Gallicchio M., **Collino M.**, Rosa AC, Benetti E, Dianzani C., Fantozzi R. Substance P induces COX-2 expression in human umbilical vein endothelial cells. XXXII National Congress of the Italian Pharmacological Society, Naples (Italy), 1-4th June, 2005
8. **Collino M.**, Interazione tra stress ossidativo e sistema recettoriale PPAR: esempio in un modello di ischemia/riperfusion cerebrale. Premio SAPIO 2005 per la Ricerca: "Aspetti patogenetici e farmacoterapeutici delle malattie neurodegenerative". Torino, 21 giugno 2005.
9. Fantozzi R., **Collino M.**, NSAIDs in cancer pain. XII International Pain Clinic Congress, Turin (Italy), July 4-7, 2006

10. **Collino M.**, Fantozzi R. Drug therapy of headache. XII International Pain Clinic Congress, Turin (Italy), July 4-7, 2006
11. Benetti E, **Collino M**, Thiemermann C, Mastrocola R, Gallicchio M, Dianzani C, Danni O, Aragno M, Fantozzi R. Glycogen synthase kinase-3 β inhibition reduces transient cerebral ischemia/reperfusion injury in the rat hippocampus. XXXIII National Congress of the Italian Pharmacological Society, Cagliari (Italy), 6-9th June, 2007
12. Rosa AC, Gallicchio M, Dianzani C, Brucato L, **Collino M**, Fantozzi R. Celecoxib modulates the expression of adhesion molecules in colon cancer cells. XXXIII National Congress of the Italian Pharmacological Society, Cagliari (Italy), 6-9th June, 2007
13. Benetti E, **Collino M**, Thiemermann C, Mastrocola R, Gallicchio M, Miglio G., Castiglia S., Dianzani C, Danni O, Aragno M, Fantozzi R. Glycogen synthase kinase-3 β inhibition reduces transient cerebral ischemia/reperfusion injury in the rat hippocampus. European Bioalpine Convention On Inflammation and Autoimmunity- Colletterto Giacosa-Torino (Italy), November 6th-7th, 2007
14. Sivarajah A, **Collino M**, Yasin M, Cuzzocrea S, and Thiemermann C "Hydrogen sulfide in disease" 7th World Congress on Trauma, Shock, Inflammation and Sepsis Munich, Germany, March 13th – 17th 2007
15. Yasin M., Shintani Y, **Collino M**, Takahashi K, Salem H, Kapoor A, Rucklidge G, Suzuki K, Thiemermann C, Bone Marrow Mononuclear Cell Therapy upon Reperfusion Reduces Myocardial Infarct Size by Activating the PI3K/Akt Survival Pathway. European Society of Cardiology ESC Congress, Monaco (Germany), 30 agosto - 3 settembre 2008
16. Shoab A Memon,, J E Kieswich, **M Collino**, S Cuzzocrea, M Aragno, R Fantozzi, S Castiglia, E Mazzon, D A Allen, A James, N Patel, M J Raftery, C Thiemermann and M M Yaqoob. Thiamine protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. 42nd Annual Meeting of the American Society of Nephrology, Renal Week 2009 - October 27 - November 1, 2009, San Diego, CA, USA
17. **Collino M**. PPAR- β/δ activation protects against renal ischemia/reperfusion injury in diabetic rats. 13th Congress of the European Shock Society, 24th-26th September 2009, Lisbon, Portugal
18. Kapoor A., Shintani Y., **Collino M**, Bailey LK., Patel NSA, Sepodes B., Tripatara B., Castiglia S, Fantozzi R., Mota-Filipe H., Sukuki K., Mitchell JA., Thiemermann C, PPAR- β/δ activation attenuates organ injury/dysfunction and inflammation caused by endotoxin. 13th Congress of the European Shock Society, 24th-26th September 2009, Lisbon, Portugal
19. Kapoor A., **Collino M**, Castiglia S, Fantozzi R., Thiemermann C, Activation of PPAR-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat. 13th Congress of the European Shock Society, 24th-26th September 2009, Lisbon, Portugal
20. **Collino M**, Benetti E, Miglio G, Castiglia S, Rosa A.C., Thiemermann C, Fantozzi R. PPAR- β/δ activation protects against renal ischemia/reperfusion injury in diabetic rats. 34th Congress of the Italian Society of Pharmacology, 14th-17th October 2009, Rimini, Italy

21. **Collino M**, Castiglia S, Manoni M, Salsini L., Chini J., Masini E., Fantozzi R. Beneficial effects of a heparin-like semi-synthetic derivative in a rat model of cerebral ischemia/reperfusion injury. 34th Congress of the Italian Society of Pharmacology, 14th-17th October 2009, Rimini, Italy
22. Miglio G., Rosa A., Rattazzi L., Benetti E., **Collino M.**, Fantozzi R. PPAR stimulation protects human podocytes from serum deprivation-induced cell death. 34th Congress of the Italian Society of Pharmacology, 14th-17th October 2009, Rimini, Italy
23. Lanzi C., Mastroianni R., Vinci M., Caterina U., Bani D., Cinci L., **Collino M.**, Masini E. Effects of a new low molecular weight bioheparin on cardiac ischemia/reperfusion-induced injury. 34th Congress of the Italian Society of Pharmacology, 14th-17th October 2009, Rimini, Italy
24. A Kapoor, Y Shintani, **M Collino**, L K Bailey, N S A Patel, B Sepodes, P Tripatara, S Castiglia, R Fantozzi, H Mota-Filipe, K Suzuki, J A Mitchell, C Thiernemann. Protective role of peroxisome proliferator-activated receptor beta/delta in cardiac dysfunction and organ injury/inflammation caused by endotoxin in mice. British Society for Cardiovascular Research Autumn 2009 Meeting Monday 7th and Tuesday 8th September, 2009, University of Oxford, U.K.
25. Kapoor A, Shintani Y, **Collino M**, Osuchowski M., Busch D., Patel NSA, Sepodes B, Castiglia S., Fantozzi R., Bailey L, Mota-Felipe H., Yaqoob MM., Suzuki K., Baharami S., Desvergne B., Mitchell JA., Thiernemann C. "Beneficial role of PPAR-beta/delta in septic shock". 14th Congress of the European Shock Society, August 31-September 2 2011, Taormina, Italy
26. Nandra K., Takahashi K., **Collino M.**, Benetti E., Wong WSF, Goh FY, Salem H., Suzuki K., Patel N., Thiernemann C. "Bone-marrow derived mononuclear cells protects against multiple organ failure in haemorrhagic shock through an Akt-dependent pathway induced by haemorrhagic shock" 14th Congress of the European Shock Society, August 31-September 2 2011, Taormina, Italy
27. **Collino M**, Pini A., Mastroianni R., Benetti E., Bani D., Manoni M., Masini E., Fantozzi R. "Protective effects of a non-anticoagulant heparin-like polysaccharide derivative on cerebral and myocardial ischemia/reperfusion injury". 14th Congress of the European Shock Society, August 31-September 2 2011, Taormina, Italy
28. R. Mastroianni, C. Lanzi, M. Fazi, N. Mugelli, **M. Collino**, D. Bani, A. Pini and E. Masini. Cardioprotective and anti-apoptotic effects of heme oxygenase-1 in post-ischemic remodeling. 35th Congress of the Italian Society of Pharmacology, 14th-17th September 2011, Bologna, Italy
29. Coldewey S.M., Khan A., Rogazzo M., **Collino M.**, Patel N.S.A, Kapoor A., Thiernemann C.. Erythropoietin reduziert die Sepsis-assoziierte myokardiale Dysfunktion in der Maus durch eine Aktivierung des Akt Signaltransduktionswegs über den beta Common-Rezeptor. 26. Wissenschaftliche Arbeitstage der DGAI. February 10 – 11 2012, Würzburg, abstract WAT12-05
30. Coldewey S.M., Khan A., Rogazzo M., **Collino M.**, Patel N.S.A, Kapoor A., Thiernemann C. Erythropoietin reduces the acute kidney injury in experimental sepsis via activation of the beta-common receptor. 7th Congress of the International Federation of Shock Societies, 35th Annual Conference on Shock, June 9 - 13, 2012 - Miami Beach, Florida
31. Kapoor A., Coldewey S.M., Khan A., Rogazzo M., **Collino M.**, Patel N.S.A, Thiernemann C. Erythropoietin attenuates cardiac injury in experimental sepsis via activation of the beta-common

- receptor. 7th Congress of the International Federation of Shock Societies, 35th Annual Conference on Shock, June 9 - 13, 2012 - Miami Beach, Florida
32. Nandra KK, Patel NS; Harwood S.; **Collino M.**; Rogazzo, M.; Yaqoob, M.; Thiemermann C. Three day pre-treatment with erythropoietin attenuates the organ injury and dysfunction induced by hemorrhagic shock in the rat by a mechanism independent of endothelial progenitor cell mobilization. 7th Congress of the International Federation of Shock Societies, 35th Annual Conference on Shock, June 9 - 13, 2012 - Miami Beach, Florida
 33. Mastrocola R., **Collino M.**, Nigro D., Medana C., Danni O., Aragno M. Advanced glycation end-products promote lipogenesis in liver of fructose-drinking mice. Oxygen Club of California World Congress 2012, 20–23 June 2012, Alba, Italy
 34. Rosa AC, Grange C, Pini A, Katebe MA, Benetti E, **Collino M**, Miglio G, Bani D, Camussi G, Chazot PL, Fantozzi R. Histamine H4 receptors are present in the kidney of diabetic rats. 48th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October, 2012, Berlin
 35. Benetti E, **Collino M**, Rogazzo M., Aragno M., Mastrocola R., Fantozzi R. High-fructose corn syrup (HFCS) diet induce an NLRP-3 inflammasome-mediated response in the kidney: protection by PPARbeta/delta agonist. 48th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October, 2012, Berlin
 36. **Collino M.**, Rogazzo M., Pini A., Benetti E., Fantozzi R., Bani D., Masini E. Acute treatment with relaxin attenuates the dysfunction induced by renal ischemia/reperfusion injury. 6th International Conference on Relaxin and Related Peptides. 8-12 October 2012. Florence, Italy
 37. **Collino M.**, Rogazzo M., Pini A., Benetti E., Fantozzi R., Bani D., Masini E. Beneficial effects of relaxin in an in vivo experimental model of ischemic acute kidney injury. SIRC workshop on new roads in cardiovascular research. 23-24 November 2012. Milan, Italy
 38. M. Rogazzo, **M. Collino**, E. Benetti, F. Chiazza, R. Mastrocola, M. Minetto, C. Thiemermann, R. Fantozzi. Inflammatory signaling and insulin resistance caused by sugar intake: modulation by PPAR- δ agonism -36th Congress of the Italian Society of Pharmacology, 23rd-26th October 2013, Turin, Italy
 39. F. Chiazza, E. Benetti, M. Rogazzo, S. Cannito, C. Paternostro, E. Novo, M. Parola, R. Fantozzi, **M. Collino**. Hepatocyte-derived microparticles promote NLRP3 inflammasome activation in HepG2 cells-36th Congress of the Italian Society of Pharmacology, 23rd-26th October 2013, Turin, Italy
 40. F. Chiazza, M. Rogazzo, E. Benetti, K. Chegarev, A. Di Stilo, R. Fruttero, J.C. Cutrin, R. Fantozzi, **M. Collino**, Nitric oxide release by an edavarone derivative containing NO donor furoxan moiety contributes to the resolution of renal injury after ischemia/reperfusion in the rat - 36th Congress of the Italian Society of Pharmacology, 23rd-26th October 2013, Turin, Italy
 41. **M. Collino**, M. Rogazzo, A. Pini, E. Benetti, F. Chiazza, A.C. Rosa, R. Fantozzi, D. Bani, E. Masini Beneficial effects of relaxin in an in vivo experimental model of ischemic acute kidney injury - 36th Congress of the Italian Society of Pharmacology, 23rd-26th October 2013, Turin, Italy

42. E. Benetti, M. **Collino**, M. Rogazzo, F. Chiazza, R. Mastrocola, M. Aragno, M. Minetto, C. Thiernemann, R. Fantozzi A nonerythropoietic peptide analog of erythropoietin decreases susceptibility to diet-induced insulin resistance - 36th Congress of the Italian Society of Pharmacology, 23rd-26th October 2013, Turin, Italy
43. Chen j, Chiazza F, **Collino M**, Sina M. Coldewey, Nimesh S.A. Patel, Christoph Thiernemann. Gender dimorphism of the cardiac dysfunction in sepsis. Thirty-Seventh Annual Conference on Shock, 7th-10th June 2014, Westin Charlotte, USA.
44. Mastrocola R, Nigro D, Chiazza F, **Collino M**, Aragno M. Fructose-Derived Advanced Glycation End-Products Evoke Skeletal Muscle Damage in Mice by Multiple Interference with SCAP-SREBP Pathway. Society for Free Radical Biology and Medicine 21st Annual Meeting, Seattle, WA, USA, 19-23 November 2014
45. R Sordi, F Chiazza, N Patel, **M Collino**, C Thiernemann. A Selective I κ B Kinase Inhibitor (IKK16) Attenuates The Organ Injury / Dysfunction Associated With Haemorrhagic Shock In The Rat. Congress of the British Pharmacological Society. 16/18-12-2014, Queen Elizabeth II Conference Centre, London, UK
46. J Chen, J Kieswich, F Chiazza, N Patel, **M Collino**, M Yaqoob, C Thiernemann. Pre-existing chronic kidney disease worsens the myocardial dysfunction caused by sepsis in mice. . Congress of the British Pharmacological Society. 16/18-12-2014, Queen Elizabeth II Conference Centre, London, UK
47. J Chen, J Kieswich, F Chiazza, Gobetti T, N Patel, Perretti M, **M Collino**, M Yaqoob, C Thiernemann. The cardiac dysfunction caused by sepsis in animals with chronic kidney disease is attenuated by inhibiting I kappa B kinase, 38th Annual Conference of the Shock-Society on Shock, Denver, CO, USA, UN 06-09, 2015
48. R Sordi, K Nandra, F Chiazza, N Patel, **M Collino**, Brohi K, C Thiernemann. Artesunate protects against the organ injury and dysfunction induced by severe hemorrhage and resuscitation. 38th Annual Conference of the Shock-Society on Shock, Denver, CO, USA, UN 06-09, 2015
49. Masini E, Nistri S, Vannacci A, Pini A, **Collino M**, Bani D. Histamine and relaxin: an intriguing connection. 44th Annual Meeting of the European-Histamine-Research-Society (EHRS), Malaga, SPAIN, MAY 06-09, 2015
50. Chiazza F, Benetti E, Aurélie Couturier-Maillard, Raffaella Mastrocola, Debora Nigro, Juan C. Cutrin, Manuela Aragno, Bernard Ryffel, Christoph Thiernemann, Fantozzi R, **Collino M**. Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice. 37th Congress of the Italian Society of Pharmacology, 27-30 October 2015, Naples, Italy
51. Chiazza F, Mastrocola R, Penna C, Nigro D, Tullio F, Saveria Femminò, Giuseppe Alloatti, Mattia Cocco, Davide Garella, Massimo Bertinaria, Roberto Fantozzi, Pasquale Pagliaro, Manuela Aragno, **Collino M**. The NLRP3 inflammasome as a new pharmacological target in myocardial ischemia/reperfusion injury in the adult rat. 37th Congress of the Italian Society of Pharmacology, 27-30 October 2015, Naples, Italy.

52. Fausto Chiazza, Elisa Benetti, Raffaella Mastrocola, Debora Nigro, Mara Rogazzo, Juan C. Cutrin, D'Antona G, Manuela Aragno, Marco A. Minetto, Chris Thiemermann, Roberto Fantozzi, **Massimo Collino**. Protective effects of a PPAR- δ agonist and a non-erythropoietic peptide derivative of erythropoietin against the diet-induced development of skeletal muscle insulin resistance and inflammation in mice. 37th Congress of the Italian Society of Pharmacology, 27-30 October 2015, Naples, Italy.
53. Chiazza F, Mastrocola R, Penna C, Nigro D, Fracasso V, Tullio F, Saveria Femminò, Giuseppe Alloatti, Roberto Fantozzi, Pasquale Pagliaro, Manuela Aragno, **Collino M**. Role of NLRP3 inflammasome in a mouse model of diet-induced exacerbation of myocardial ischemia/reperfusion injury. 37th Congress of the Italian Society of Pharmacology, 27-30 October 2015, Naples, Italy.
54. Sordi R, Chiazza F, Florence L Johnson, Nimesh S A Patel, Karim Brohi, **Collino M**, Thiemermann C. Pharmacological inhibition of I κ B Kinase reduces the multiple organ dysfunction associated with hemorrhagic shock in rat. 37th Congress of the Italian Society of Pharmacology, 27-30 October 2015, Naples, Italy.
55. **Collino M**. Cardiometabolic diseases and the inflammasome: a key and innovative pharmacological target? 8th Euro Global Diabetes Summit and Medicare Expo, Nov 3-5, 2015, Valencia, Spain
56. F Johnson, N Patel, **M Collino**, E Bennetti, C Thiemermann. The late inhibition of inhibitor of I κ B kinase attenuates acute kidney injury and the subsequent development of fibrosis in a rat model of ischemia/reperfusion injury. XVI Congress of the European Shock Society, September 24 -26, 2015, Cologne, Germany.
57. J Chen, J Kieswich, F Chiazza, Gobetti T, N Patel, Perretti M, **M Collino**, M Yaqoob, C Thiemermann. The cardiac dysfunction caused by sepsis in animals with chronic kidney disease is attenuated by inhibiting I kappa B kinase. XVI Congress of the European Shock Society, September 24 -26, 2015, Cologne, Germany.
58. R Sordi, KK Nandra, F Chiazza, NSA Patel, K Brohi, **M Collino**, C Thiemermann. Trauma organ protection with artesunate: preclinical efficacy of an antimalarial drug with excellent safety profile and planned phase II RCT. XVI Congress of the European Shock Society, September 24 -26, 2015, Cologne, Germany.
59. Mastrocola R, **Collino M**, Nigro D, Medana C, Dal Bello F, Chiazza F, Boccuzzi G, Aragno M. Fructose-derived advanced glycation end-products induce a negative crosstalk between lipogenesis and muscle reprogramming in mice through SREBP-1c. 51st EASD Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden, 14-18 September 2015.
60. E. Benetti, G. Vitarelli, **M. Collino**, R. Mastrocola, J.C. Cutrin, F. Chiazza, D. Nigro, R. Fantozzi. Effects of empagliflozin in a murine model of diet-induced insulin resistance: A role for NLRP3 inflammasome inhibition? 51st EASD Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden, 14-18 September 2015.

61. SM Coldewey, E Benetti, **M Collino**, M Bauer, A Huwiler, C Thiemermann. Enhanced sphingosine-1-phosphate levels ameliorate murine septic cardiomyopathy. 28th annual congress of the European Society of Intensive Care Medicine, 3-7th October 2015, Berlin, Germany
62. S Femminò, F Chiazza, R Mastrocola, F Tullio, C Penna, D Nigro, G Alloatti, M Cocco, D Garella, M Bertinaria, R Fantozzi, M Aragno, **M Collino**, P Pagliaro. Is NLRP3 inflammasome a new pharmacological target in myocardial ischemia/reperfusion injury. Congresso Nazionale della Società Italiana di Ricerche Cardiovascolari, 26-28 November 2015, Imola, Italy
63. F Tullio, F Chiazza, R Mastrocola, C Penna, D Nigro, V Fracasso, G Alloatti, R Fantozzi, M Aragno, **M Collino**, P Pagliaro. Exacerbation of myocardial ischemia/reperfusion injury induced by high fat high fructose diet: role of NLRP3 inflammasome. Congresso Nazionale della Società Italiana di Ricerche Cardiovascolari, 26-28 November 2015, Imola, Italy
64. Chen J, Kieswich JE, Chiazza F, Moyes AJ, Gobbetti T, Purvis GS, Salvatori DC, Patel NS, Perretti M, Hobbs AJ, **Collino M**, Yaqoob MM, Thiemermann C. I κ B Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in mice with CKD. 8th Congress of the International-Federation-of-Shock-Societies Location: Tokyo, JAPAN Date: OCT 03-05, 2016
65. Thiemermann C., Sordi R, Nandra KK, Chiazza F, Johnson FL, Cabrera CP, Torrance HD, Yamada N, Patel NS, Barnes MR, Brohi K, **Collino M**. Artesunate Protects Against the Organ Injury and Dysfunction Induced by Severe Hemorrhage and Resuscitation. 8th Congress of the International-Federation-of-Shock-Societies Location: Tokyo, JAPAN Date: OCT 03-05, 2016
66. Spallotta F, Cencioni C, Atlante S, Garella D, Cocco M, Mori M, Mastrocola R, Kuenne C, Guenther S, Nanni S, Azzimato V, Zukunft S, Kornberger A, Sürün D, Schütgen F, von Melchner H, Di Stilo A, Aragno M, Braspenning M, van Criekinge W, De Blasio MJ, Ritchie RH, Zaccagnini G, Martelli F, Farsetti A, Fleming I, Braun T, Beiras-Fernandez A, Botta B, **Collino M**, Bertinaria M, Zeiher AM, Gaetano C. Cardiac Epi-Metabolic Signature Revealed by Integrated Omics Approach in Diabetic Patients: Rescue by Active DNA Demethylation via TET-TDG Complex Reactivation Conference: Scientific Sessions of the American-Heart-Association / Resuscitation Science Symposium Location: New Orleans, LA Date: NOV 12-16, 2016
67. Martin L, Chen J, Elisabeth Zechendorf, Chiazza F, Oggero S, **Collino M**, Gernot Marx, Tobias Schuerholz, and Christoph Thiemermann Role of the β -D-endoglucuronidase heparanase in septic cardiomyopathy. 40th Annual Conference on Shock (Fort Lauderdale, Florida) June 3 - 6, 2017
68. Yamada N, Lukas Martin, Elisabeth Zechendorf, Chiazza F, Varrone B, **Collino M**, Joanna Shepherd, Lena Heinbockel, Wilmar Correa, Klaus Brandenburg, Gernot Marx, Tobias Schuerholz, Karim Brohi, Christoph Thiemermann. A novel synthetic, host-defence peptide protects against organ injury/dysfunction in a rat-model of severe hemorrhagic shock. 40th Annual Conference on Shock (Fort Lauderdale, Florida) June 3 - 6, 2017
69. Collino, M.; Chiazza, F.; Collotta, D.; **Collino, M**, Cento, AS; Nigro, D; Bitonto, V; Cutrin, JC; Aragno, M; Mastrocola, R. The AGEs inhibitor pyridoxamine prevents kidney injury and dysfunction in mice fed high-fat high-fructose diet Conference: 53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Lisbon, PORTUGAL Date: SEP 11-15, 2017

70. Mastrocola, R.; Cento, A. S.; Chiazza, F.; Ferrocino, I.; Bitonto, V.; Nigro, D.; Querio, G.; Rantsiou, K.; Cutrin, JC.; Aragno, M.; Liberto, E.; Masini, E.; Cordero, C.; Cocolin, L.; **Collino, M.** Toxicological impact of high fructose intake on gut microbiota and liver/intestine integrity: Any differences between solid and liquid formulations? Conference: 53rd Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Lisbon, PORTUGAL Date: SEP 11-15, 2017
71. Purvis, GSD.; Chiazza, F.; **Collino, M.**; Solito, E.; Thiemermann, C. Endogenous Annexin-A1 is a Protective Determinant in HFD-induced Insulin Resistance and Diabetic Nephropathy Conference: Annual Meeting of the American-Society-for-Pharmacology-and-Experimental-Therapeutics (ASPET) at Experimental Biology Meeting Location: Chicago, IL Date: APR 22-26, 2017
72. Baratta F, Simiele M, Pignata I, Beatrice Iozzino, Irene De Pellegrini, Riccardo Torta, Anna De Luca, **Collino M**, D'Avolio A, Paola Brusa. Impact of Different Procedures of Galenic Formulations of Cannabis on Cannabinoids Contents. The International Annual Congress on Controversies on Cannabis-Based Medicines 25-26 June 2018, Vienna, Austria.
73. Cento Alessia S.; Chiazza F.; Collotta D.; Barutta F.; Aragno M.; Scheijen J.; **Collino M**, Gaens KH; Schalkwijk CG; Wouters K; Mastrocola R. Genetic deletion of RAGE in Dbdb mice interferes with AGEs receptors and detoxifying systems in liver. Conference: 19th Biennial Meeting of the Society-for-Free-Radical-Research-International (SFRRRI) Location: Lisbon, PORTUGAL Date: 2018
74. Cento Alessia S.; Felicetti F.; Mastrocola R.; Collotta D.; **Collino M**; Aragno M.; Brignardello E. Redox unbalance and inflammation in long-term survivors of childhood acute lymphoblastic leukemia Conference: 19th Biennial Meeting of the Society-for-Free-Radical-Research-International (SFRRRI) Location: Lisbon, PORTUGAL Date: 2018.
75. Cento A, Gaens KH; Collotta D; Chiazza F; Barutta F; Scheijen J; Aragno M; **Collino M**, Wouters K; Schalkwijk CG; Mastrocola R. AGEs induce alterations of sphingolipids metabolism in the liver of genetically- and diet-induced diabetic mice. Conference: 54th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Berlin, GERMANY Date: OCT 01-05, 2018.
76. Mastrocola R., Cento Alessia S.; Collotta D; Chiazza F; Barutta F; Scheijen J; Aragno M; Gaens KH; **Collino M**, Schalkwijk CG; Wouters K; Genetic deletion of RAGE in db/db mice interferes in the liver with other AGE-receptors and AGE-detoxifying systems sustaining lipogenesis and inflammation. Conference: 54th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD) Location: Berlin, GERMANY Date: OCT 01-05, 2018.
77. **Collino M**, Liberto E, Mastrocola R, Ferrocino I, Chiazza F, Cento AS, Collotta D, Rantsiou K, Ilea A, Aragno M, Cocolin L, Bicchi C, Cordero C. The form makes the difference: unrevealing the differential susceptibility to sugar-induced metabolic derangements evoked by liquid and solid fructose formulations. EuroNutrition 2018. XII Italian Food Chemistry Congress, "Chimali 2018", September 18-20, 2018 Camerino, Italy

78. Liberto E, Cordero C., Mastrocola R, Ferrocino I, Chiazza F, Cento AS, Collotta D, Rantsiou K, Aragno M, Cocolin L, Bicchi C, **Collino M**, “Comprehensive two-dimensional gas chromatography as highly informative fingerprinting tool to study the impact of fructose formulation on mice’s microbiota and its volatile metabolome signatures” EuroNutrition 2018. XII Italian Food Chemistry Congress, “Chimali 2018”, September 18-20, 2018 Camerino, Italy
79. Cordero C., Liberto E, Chiazza F, Mastrocola R, Stephen E. Reichenbach, Bicchi C, **Collino M**. “Unrevealing the differential impact of liquid and solid fructose in mice metabolic signatures by comprehensive two-dimensional gas chromatography” EuroNutrition 2018. XII Italian Food Chemistry Congress, “Chimali 2018”, September 18-20, 2018 Camerino, Italy
80. Femminò S, Chiazza F, Collotta D, **Collino M**, Manuela Aragno, Massimo Bertinaria, Pasquale Pagliaro, Claudia Penna. “Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects?” 4th SIRC Forum on new roads in cardiovascular research. October 6th 2018, Rome, Italy
81. Chiazza F, Pintana H, Tammen H, Lietzau G, Nyström T, Klein T, **Collino M**, Darsalia V, Patrone C. “The effect of the DPP-4 inhibitor linagliptin to improve functional outcome after stroke is mediated by the CXCR4/SDF-1 pathway” 4th SIRC Forum on new roads in cardiovascular research. October 6th 2018, Rome, Italy
82. Cento A, Collotta D, Chiazza F, Aragno M, **Collino M**, Mastrocola R. “Inhibition of AGEs by pyridoxamine prevents diet-induced systemic inflammation and skeletal muscle insulin resistance by restoring SphK1/S1PR3/RhoA signalling” 55th EASD Annual Meeting 16-20 September 2019. Barcelona, Spain
83. Gaudio G, Collotta D, Chiazza F, Mastrocola R, Alessia Cento, Francesca Fava, Aragno M, **Collino M**, Tuohy K. “Advanced glycation end products (AGEs) in metabolic disease: linking diet, inflammation and microbiota” 13th European Nutrition Conference Federation of European Nutrition Societies (FENS) 2019, 15 – 18 October 2019, Dublin, Ireland.
84. Verta R., Berardo C., Siciliano V., Di Pasqua L.G., Collotta D., Nicoletti F., Vairetti M., **Collino M.**, Ferrigno A. “The mGlu5 negative allosteric modulator MPEP protects against cold ischemic injury in rat livers from donor after cardiac death.” 39th Congress of the Italian Society of Pharmacology, 20th-23rd November 2019, Florence, Italy
85. Collotta D, Chiazza F, Mastrocola R, Manuela Aragno, Chiara Cordero, Erica Liberto, Rosa M. Sáinz, Vanesa Cepas, Aranka Ilea, Bianca A. Boşcab, Jared Q. Gerlach, Marie Le Berre, Lokesh Joshi, Thomas Henle, Friederike Manig, Michael Hellwig, **M. Collino**. “Salivary Advanced Glycation End Products (AGEs) as novel biomarkers in evaluation of risk factors for diet-related diseases: results from the European Network SALIVAGES” 39th Congress of the Italian Society of Pharmacology, 20th-23rd November 2019, Florence, Italy
86. Chiazza F, Femminò S, Collotta D, Zicola E, Aragno M, Bertinaria M, Pasquale Pagliaro, Claudia Penna, **Collino M**. “Do P2Y12 receptor antagonism and NLRP3 inhibition exert additive cardioprotective effects against ischemia/reperfusion injury?” 39th Congress of the Italian Society of Pharmacology, 20th-23rd November 2019, Florence, Italy

87. Collotta, D, Cento A, Chiazza F, Verta R, Thomas Henle, Friederike Manig, Michael Hellwig, Giulia Gaudioso, Francesca Fava, Kieran Tuohy, Aragno M, Mastrocola R, **Collino M**. “Role of exogenous dietary advanced glycation end products (AGEs) in the cross-talk mechanisms linking diet, microbiota and metabolic inflammation “. 39th Congress of the Italian Society of Pharmacology, 20th-23rd November 2019, Florence, Italy
88. Collotta D, Cordero C, Jared Q. Gerlach, Liberto E, Chiazza F, Marta Cialiè Rosso, Mele C, Mai S, Stephen E. Reichenbach, Qingping Tao, Marie Le Berre, Mastrocola R, Aragno M, Lokesh Joshi, Bicchi C, Marzullo P, Aimaretti G, **Collino M**. “Pilot study on comparative profiling of biofluids (serum, urine and saliva) from metabolically healthy and metabolically unhealthy obese subjects” 39th Congress of the Italian Society of Pharmacology, 20th-23rd November 2019, Florence, Italy
89. Chiazza F; Sordi R; Collotta D; Migliaretti G, Romain A Colas; Paul Vulliamy; Karim Brohi; Jesmond Dalli; **Collino M**, Thiemermann C Resolvin D1 attenuates the organ injury associated with hemorrhagic shock” 39th Congress of the Italian Society of Pharmacology, 20th-23rd November 2019, Florence, Italy
90. Di Pasqua L G., Palladini G, Berardo C, Verta R., Siciliano V, Richelmi P, Collotta D., **Collino M**, Vairetti M, Ferrigno A. “Early and transient activation of MAPKs and matrix metalloproteinases contributes to hepatic ischemia/reperfusion injury” 39th Congress of the Italian Society of Pharmacology, 20th-23rd November 2019, Florence, Italy
91. Penna, C; Femmino, S; Chiazza, F; Collotta, D; Aragno, M; Bertinaria, M; **Collino, M**; Pagliaro, P. Ischemia and reperfusion injury: modulation of damage with ticagrelor and specific NLRP3 inflammatory inhibitor. 80th SIC National Congres. Rome, ITALY, 12-15, December 2019
92. Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C, Verta R, Alves GF, Gaudioso G, Fava F, Yaqoob M, Aragno M, Tuohy K, Thiemermann C, **Collino M**. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Electr Network, Sept 21-25, 2020
93. Mastrocola R, Collotta D, Gaudioso G, Le Berre M, Cento AS, Ferreira Alves G, Chiazza F, Verta R, Bertocchi I, Manig F, Hellwig M, Fava F, Cifani C, Aragno M, Henle T, Joshi L, Tuohy K, **Collino M** Effects of Exogenous Dietary Advanced Glycation End Products on the Cross-Talk Mechanisms Linking Microbiota to Metabolic Inflammation. 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Electr Network, Sept 21-25, 2020
94. Collotta D, Hull W, Mastrocola R, Chiazza F, Cento AS, Murphy C, Verta R, Alves GF, Gaudioso G, Fava F, Yaqoob M, Aragno M, Tuohy K, Thiemermann C, **Collino M**. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice. 40th Congress of the Italian Pharmacological Society, Digital Edition, March 9-13, 2021
95. Collotta D, Purvis GSD, Aranda-Tavio H, Chiazza F, O’Riordan CE, Zeboudj L, Mohammad S, Verta R, Guisot NES, Bunyard P, Yaqoob MM, Greaves DR, Thiemermann C, **Collino M**. Inhibition of Bruton’s TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation. 40th Congress of the Italian Pharmacological Society, Digital Edition, March 9-13, 2021.

96. **Collino M.** Pharmacological Targeting of key proximal drivers of metaflammation in diet-induced metabolic diseases. Invited Speaker. 40th Congress of the Italian Pharmacological Society, Digital Edition, March 9-13, 2021.
97. E. Aimaretti, F. Felicetti, F. Dal Bello, F. Gatti, M. Cassader, C. Cifani, F. Fagioli, M. Aragno, **M. Collino**, E. Brignardello. The systemic inflammatory response in hodkigkin lymphoma survivors are advanced glycation end products potential players. 1st meeting of the Immunopharmacology Working Group of the Italian Pharmacological Society, Perugia, November 24-26, 2021.
98. D. Collotta, W. Hull, R., Mastrocola, E. Aimaretti, F. Chiazza, S. Cento, C. Murphy, R. Verta, G. Ferreira Alves, G. Gaudio, F. Fava, M. Aragno, K. Tuohy, C. Thiemermann, **M. Collino**. Potential repositioning of baricitinib for preventing diet-induced metabolic abnormalities: an in-vivo study. 1st meeting of the Immunopharmacology Working Group of the Italian Pharmacological Society, Perugia, November 24-26, 2021.
99. G. Einaudi, G. Ferreira Alves, D. Collotta, R. Mastrocola, F. Penna, C. Fornelli, E. Aimaretti, M. Aragno, M. Bertinaria, C. Cifani, **M. Collino**. Pharmacological targeting of cyclooxygenase to counteract metaflammation in an in-vivo model of diet-induced metabolic derangements. 1st meeting of the Immunopharmacology Working Group of the Italian Pharmacological Society, Perugia, November 24-26, 2021.
100. G. Ferreira Alves, E. Aimaretti, G. Einaudi, R. Mastrocola, J. Garcia Oliveira, D. Collotta, M. Aragno, C. Thiemermann, D. Fernandes, **M. Collino**. Inhibition of FAK-PYK2 pathway protects against organ damage and prolongs the survival of septic mice. 1st meeting of the Immunopharmacology Working Group of the Italian Pharmacological Society, Perugia, November 24-26, 2021.